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ABSTRACT
The transmissible spongiform encephalopathies (TSEs) are a class of
neurodegenerative diseases that are characterized by proteinaceous deposits in
the brain. The deposits consist largely of an abnormal form of prion protein
which is highly aggregated and resistant to degradation by proteases. The
function of prion protein (PrP) is unknown and its normal form (PrPC) is
sensitive to protease digestion. Some of the TSEs include scrapie in sheep, mice,
and hamsters, bovine spongiform encephalopahty, and Creutzfeldt-Jakob disease
in humans. Animals with scrapie accumulate a disease-specific form of PrP
designated PrPSC. The identity of the infectious agent of the TSEs is unclear. No
conventional agent or disease-specific nucleic acid has been found and
treatments that destroy most normal viruses have no effect. Based on that
information the infectious particle has been surmized to consist solely of protein.
The "protein only" theory has been strengthened by the discovery of PrP and that
preparations of PrPSc are greatly enriched for infectivity. Previously, the
simplest system producing protease-resistant PrP was cell culture. Here is
described a system that produces protease-resistant PrP in vitro. This system was
used to study the mechanism of the conversion of PrPC to the protease-resistant
form. A threshold concentration of aggregates of PrPS c was required for
conversion. Guanidine-HCI solubilized PrPSC had no converting activity. The
need for aggregates and a threshold concentration favors a seeded
polymerization mechanism of conversion. The system was also used to study
species barriers and different strains of scrapie. Different combinations of mouse
and hamster PrPs were used in conversion reactions. The in vitro conversion
results correlated with infectivity data on transmission. Scrapie strains with
different PrPSc N-terminal protease cleavage sites were used with this system.
These different cleavage sites were passed to newly-resistant PrPC depending on
which strain was in the reaction. This system provided evidence that a "protein
only" theory is compatible with the properties of TSEs.
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Chapter 1
The Transmissible Spongiform Encephalopathies
The transmissible spongiform encephalopathies (TSEs) are a class of
neurodegenerative diseases characterized by abnormal proteinaceous deposits in
the brain. A wide range of mammals (including humans) are susceptible to
various types of TSEs. Scrapie, the most widely studied TSE, is naturally present
in sheep. Other TSEs in animals include bovine spongiform encephalopathy
(BSE), transmissible mink encephalopathy (TME), and chronic wasting disease in
elk and mule deer. TSEs in humans include Creutzfeldt-Jakob disease (CJD),
Gerstmann-Straussler-Schenker syndrome (GSS), kuru, and fatal familial
insomnia (FFI).
The TSEs are sporadic, infectious, and genetic diseases which makes them
unique. CJD affects about one person per million per year with about 5% of the
cases being caused by germ-line mutations (familial cases). CJD can be
accidentally transmitted between people through medical procedures (iatrogenic
transmission). Accidental transmissions have been caused by cornea transplants
from CJD patients, contaminated surgical instruments, and contaminated growth
hormones, for example. The unusual resistance of the infectious agent to normal
sterilization procedures increases the likelihood of these instances, which account
for about 1% of all CJD cases. More than 90% of CJD cases are sporadic and can
not be traced to a mutation or specific source of infection.
CJD is characterized by dementia, ataxia (a loss of muscle coordination),
and the formation of small holes in the brain known as spongiform degeneration.
This spongiform degeneration is the result of a loss of neurons. CJD is often
accompanied by abnormal proteinaceous deposits known as amyloid plaques.
The onset of CJD can be months to years after infection, but once the disease
presents itself a gradual deterioration of mental capabilities ensues. The
deterioration ends in death usually within a year of onset. Heparin sulfates have
been shown to offer some protection to mice inoculated with scrapie,7 but as of
now there is no way to stop the deterioration and the disease is always fatal.
GSS is a familial version of CJD with different pathology. All GSS cases
are accompanied by the formation of amyloid plaques2 and it is transmissible.
FFI, caused by a point mutation and polymorphism, results in incurable
insomnia, selective atrophy of thalamic nuclei, and dysautonomia (abnormal
functioning of the autonomic nervous system). FFI is much less characterized by
spongiform degeneration than CJD,3 but nevertheless has recently been shown to
be transmissible. 4 Kuru was found to affect a small population in New Guinea
that practiced ritual cannibalism. In 1976, D. Carlton Gadjusek won the Nobel
Prize in medicine for the transmission of kuru to primates and the assumption
that its spread occurred through the cannibalism. As the practice of cannibalism
has ceased, the disease has been mostly eliminated.5
The most studied TSEs are scrapie, originally from sheep and goats, and
BSE or "mad cow disease." Scrapie has been recognized for hundreds of years,
but BSE became a problem in Great Britain in 1985. Scrapie is passed between
sheep but the source of BSE is uncertain. One theory of the cause of the epidemic
is that scrapie-infected sheep were processed and added to cattle feed. As BSE
may have originated through cows exposed to sheep scrapie, the risk to humans
eating infected beef is unknown. In Great Britain, it is now feared that cases of a
new CJD strain may have been caused by ingestion of BSE. This report has
resulted in many countries banning British beef. More BSE information is
presented in the introduction to chapter 4.
Early studies of the scrapie agent
As might be expected, the early studies assumed that the TSEs were
transmitted through some conventional agent. Sigurdarson defined the TSEs as
slow infections based upon studies of chronic diseases afflicting Icelandic sheep.6
Slow infections have characteristics of acute and chronic diseases. In acute
diseases, the host will either fight off the infection or die rapidly. Chronic
diseases are associated with extended remission periods and then reoccurrence.
The term slow infection does describe the TSEs regardless of the identity of the
infectious agent and how the host fights an infection. The TSEs have a variable
period of up to decades with no symptoms after infection, but the course of the
disease after onset is rapid.
Hadlow later found pathological similarities between scrapie and kuru
and suggested that the diseases may be related even though they were from
different species. 7 In 1965, Gadjusek, Gibbs, and Alpers transmitted kuru to
chimpanzees 8 and later transmitted CJD to chimpanzees and monkeys 9, 10 which
showed that the diseases were related. Scrapie in sheep was previously known
to be transmissible and this suggested that all TSEs were related. Chandler was
able to transmit sheep scrapie to mice which greatly facilitated its study.11 The
use of mice to study scrapie was an improvement over sheep, but the course of
the disease was still about a year. The development of a line of scrapie in Syrian
golden hamsters12, 13 aided studies by further reducing the time of the course of
the disease. The bioassay for infectivity was further refined through the use of
incubation time, the time from infection to the appearance of clinical symptoms,
instead of death as an endpoint.14
Because the infectious agent of the TSEs had not been identified, studies
were done that allowed speculation on its identity. The infectious agent was
resistant to treatment by heat and acetylethyleneimine, 15 which would be
expected to inactivate nucleic acid. Treating the infectious agent with small
doses of ionizing radiation at 254 nm, which would have inactivated typical
viruses, also did not affect the infectivity.16 The large dose of 254 nm radiation
required for inactivation suggested that the agent was smaller than most viruses.
The involvement of nucleic acids in the infection process remains controversial
today as does the identity of the agent. These treatments aimed at altering
nucleic acids would not have affected the protein that was later purified from
infectious preparations and postulated to be the infectious agent.
Purification of prion protein from infectious preparations
The "recent" studies of scrapie began in 1981 with the identification of
scrapie associated fibrils by Merz and coworkers using electron microscopy
(EM).17 Normal mice did not contain the fibrils and later humans with CJD were
also found to have them.18 Originally these fibrils were classified as non-
amyloid, but this was later shown to be incorrect. 19 Prusiner and coworkers
purified a protein from scrapie brain extracts through low-speed centrifugation,
precipitation from ethylene glycol and ammonium sulfate, enzymatic digestion,
and sedimentation through a sucrose gradient.20 The purified protein was
named prion protein or PrP. Prion stands for "proteinaceous infectious particle."
The purification procedure for PrP was shown to concentrate infectivity 100 to
1000 fold by subsequent bioassay using hamsters. The major constituent of the
enzymatically digested fractions enriched for infectivity was a 27-30 kDa protein
named PrP 27-30. PrP 27-30 also formed fibrils which were probably identical to
those identified by Merz. At this time it was suggested that the infectious agent
in scrapie was made up solely of PrP. This "protein-only" hypothesis, however,
was first suggested in 1967 by J.S. Griffith,21 a mathematician at Bedford College
in London, based on earlier inactivation studies and without the knowledge of a
scrapie-specific protein. Other investigators were also able to find prion protein
in infectious preparations. Diringer et al. reported a similar 26 kDa protein and
showed a correlation between the presence of fibrils and infectivity. 22
Characterization of PrP 27-30 was then undertaken. The N-terminal
sequence of PrP was determined from protein purified by size exclusion HPLC. 23
Using this sequence information, a cDNA library was made and then the full
sequence of PrP was determined.24 Antibodies to PrP peptides were prepared
and immunoblotting indicated that PrP was present in normal as well as scrapie-
infected hamster brains. However, the amount of PrP was much higher in
scrapie cases. Similar levels of mRNA were found in the diseased and normal
brains.25 The mouse26 and human27' 28 PrP sequences were found to be highly
homologous with hamster PrP and no other known protein (Fig. 1).
The open reading frame of PrP is 254 amino acids. The first 22 amino
acids are a signal peptide that is cleaved during biosynthesis.29, 30 After the
signal peptide is a region that contains 5 octarepeats of sequence: PHGGGWGQ.
Between residues 100 and 150 is a highly hydrophobic sequence that is very
strongly conserved in all species of PrP. In naturally produced PrP, a
glycophosphatidyl inositol (GPI) anchor is attached to Ser 231 and the remainder
of the protein is cleaved as this anchor is added.31 Asparagine residues are
variably glycosylated at positions 181 and 197.32 The cysteines at positions 179
and 214 form a disulfide linkage.30 Overall PrP has a net positive charge of 18 at
pH 7.4. The bulk of this positive charge resides in the N-terminal portion of the
molecule.
PrP is found in a normal and disease-specific form
While PrP is found in normal and scrapie-infected hamster brains, these
forms were found to be very different. The normal or cellular form of PrP was
designated PrPC and the scrapie-associated form was named PrPSc. No covalent
difference has been found between the forms33 that can explain their
substantially different properties. Preparations of PrPC are not infectious while
preparations of PrPsc are. They also differ in their solubility, sedimentation, and
resistance to degradation by enzymes. PrPC is easily extracted by detergents and
PrPSc is not. Ultracentrifugation can separate the forms because in the absence of
denaturing treatment PrPSc is largely aggregated. A limited protease treatment
will remove PrPC from PrPsc preparations, as PrPC is readily degraded by
proteases and PrPSc is partially resistant to them. Proteinase K (PK), a serine
protease, is typically used 34 although resistance to other enzymes such as trypsin
and chymotrypsin is observed. Treating PrPSc with PK for one hour results in
digestion limited to the first approximately 67 amino acids (cleavage around
residue 90) which accounts for the lost 6-7 kDa.23, 29 However, PrPsc will be
fully digested after a 24 hour treatment. Without enzymatic treatment all PrP is
primarily 33-35 kDa. A limited digestion of PrPSc preparations does not affect
the infectivity, but seems to be necessary for PrPSC to form amyloid fibrils. 35
PrPC is expressed at very low levels in cells and PrPSC accumulates
primarily in extracellular space of the brains of infected animals. The properties
and quantity of PrPSc make it easier to purify, although trace amounts of RNA,
DNA, heparin, etc. are found in all preparations. It is very difficult to obtain and
purify PrPC in even microgram amounts. PrPS c was purified and spectra were
taken of it. Caughey and coworkers found by Fourier transform infrared (FTIR)
spectroscopy that PrPSC had about 50% gi-sheet structure. 36 PrPC was purified by
Pan et al. 37 in enough quantity for FTIR spectroscopy. FTIR indicated substantial
a-helix and random coil secondary structure present in PrPC. Covalent
modifications between the two forms of PrP have not been found, suggesting
that the only difference between the isoforms is a conformational change. This
change may be sufficient to produce TSEs.
Genetic studies of PrP
The TSEs are notable in that they are infectious, sporadic, and genetic
diseases. Sequencing PrP from individuals in families that have a history of TSEs
has found a large number of single mutations that predict a TSE will occur.
However, infectivity from all CJD brains is similar. Whether the CJD was
sporadic, inherited, or due to infection does not seem to affect infectivity levels.
No mutations in other proteins have been found to explain their propensity to
acquire TSEs.
The gene for PrP (PRNP) is located on the short arm of chromosome 20
and the homologous region of mouse chromosome 2.28, 38 Some of the 18
mutations that have been found associated with TSEs in humans to date are the
following: Pro to Leu at codon 102 with GSS;39, 40 Ala to Val at codon 117 with
GSS;41, 42 Asp to Asn at codon 178 with CJD and FFI;3 and Glu to Lys at codon
200 with CJD.43 A different mutation that accounts for some CJD is the insertion
of several extra octarepeat units.44' 45 Most of the diseases caused by these
mutations in humans have been transmitted to animals.
How these mutations affect PrPC and PrPsc or why so many varied
mutations could end with the formation of PrPsc is unknown. Possibly, the
mutations affect the folding or unfolding of PrPC which aids in the formation of
the disease specific form. Perhaps PrPSC aggregates are stabilized by the
mutations. Mutations that cause TSEs is evidence that PrP plays an essential role
in the TSEs, but the argument can be made that PrP affects some other system or
allows an individual to be susceptible to some ubiquitous agent.
Transgenic studies of PrP and the species barrier
The resistance to infection or extended incubation times that result when
interspecies TSE transmissions are attempted are called species barriers. Mice
inoculated with Chandler strain scrapie from other mice will get sick in
approximately 120 days. Inoculating the same material into hamsters will cause
scrapie in approximately 380 days.46, 47 This increase in time is the species
barrier. This 380 day incubation period will be reduced after several serial
passages in hamsters. Hamster 263K scrapie will cause disease in hamsters in
about 60 days, but does not cause disease in mice.48 In this case the barrier is so
large that total resistance is observed.
To learn how changing PrP affected the species barrier, transgenic (Tg)
mice and hamsters were produced. The effect on the species barrier shed light on
how PrP functions in the TSEs. First, the PRNP for the Syrian hamster was
placed into mice. These mice would then produce hamster and mouse PrP (they
differ at 16 residues). These Tg mice were viable and susceptible to infection by
both mouse and hamster scrapie without any barrier.49 The PrPSC produced in
these Tg animals depended upon which species of scrapie was introduced.
Inoculating Tg mice with hamster scrapie agent resulted in formation of only
hamster PrPSc (HaPrPSc). Infected with mouse scrapie agent, only mouse PrPsc
(MoPrPsc) was produced. 50 If the Tg mice had been inoculated with hamster
scrapie, subsequent brain homogenates inoculated into normal hamsters resulted
in no species barrier. This result strongly supports the hypothesis that the
species barrier was due to the incompatibility of different species' PrP. Other Tg
experiments have been done that are not as conclusive. Mice with the codon 102
Pro to Leu mutation that leads to GSS in humans spontaneously develop a
neurodegenerative disease. However, the pathology is different from what is
seen in humans and the disease is not transmissible. 50 Therefore, this mutation
in mice may not cause a TSE. Mice that express many fold excess PrP also
develop a neurodegenerative disease that may not be scrapie because it is also
not transmissible.51
An important Tg experiment was done by Weissman and coworkers using
mice with no functioning PrP gene or "knockout" mice.52 These mice are viable
and seem normal under laboratory conditions. However, recent studies of
hippocampal tissue from these mice have indicated that long term potentiation
abnormalities may be present.53 These mice were inoculated with mouse scrapie
to determine their incubation period. It was found that the "knockout" mice were
not susceptible to scrapie, illustrating that PrP is a necessary component of
scrapie pathology. Recently, experiments with mice expressing human and/or
mouse PrPC have shown that CJD is much more easily transmitted to the
knockout mice expressing only human PrPC.54 CJD transmission to mice is
hindered when only 5-10% of the total PrPC expressed is of the mouse sequence.
The authors state that this suggests a required species-specific non-PrP cofactor
in the conversion process. However, a putative cofactor remains to be identified.
TSE strains
Strains of TSEs that have different pathologies exist within the same
species. Many strains are stable and will maintain their distinct pathologies after
indefinite serial passages. The existence of different strains of TSEs has been
used as evidence that different virus strains are causing the diseases. The
pathological differences include different patterns of spongiform degeneration,
different areas of the brain being affected, and widely varying incubation times.
Most strains have resulted through interspecies TSE transmissions and different
serial passage histories.
For example, 263K, which is a widely used strain of hamster scrapie, came
from passage of sheep scrapie to micell which became the Chandler strain. After
the fifth serial passage of this mouse scrapie in Syrian golden hamsters, the 263K
strain emerged.12 The characteristics of this strain in hamsters does not vary
after indefinite serial passages.
Biosynthesis of PrPc and PrPSc in cell culture
The production of scrapie infectivity occurs in the brains of inoculated
hamsters and other animals, but the simplest system that is known to produce
infectivity is a neuroblastoma cell system. While the function of PrPC is
unknown, this system has been used to study the biosynthesis of PrPC and PrPsc.
Neurons express more PrP than other cells and also have the highest
concentration of PrP mRNA. For this reason infected brains are used as the
source of PrPSc and neural cells are used to study the biosynthesis.
Cell culture studies of PrP biosynthesis were made possible with the
development of a chronically infected murine neuroblastoma cell line. After an
initial treatment with mouse scrapie, these cells continuously produce PrPS c and
infectivity. Pulse-chase metabolic labeling using 35S-methionine followed by an
immunoprecipitation with a PrP antibody was done.55 35S-PrpC was found two
minutes after addition of the 35S, but labeled PrPSc was not detected until one
hour later. 35S-PrPC concentration was found to peak about two hours after
labeling and it was degraded in the cell with a half-life of about four hours. 35S-
PrPSc continued to increase up to 45 hours later with half-maximal labeling at 6
hours. There was no evidence of degradation or turnover occurring. The
distinction between PrPC and PrPSC was made using PK digestion which showed
that PrPC was the precursor of PrPsc. Only 3% of the total 35S-PrPC that was
produced eventually became 35S-PrpSc. Phosphatidylinositol-specific
phospholipase C (PIPLC) cleaves the GPI anchor of PrP and releases it from the
cell surface. The use of PIPLC on the neuroblastoma cells after metabolic
labeling inhibited the conversion to PrPsc, suggesting the conversion occurs after
PrPC is brought to the cell surface.
What is the infectious agent in the TSEs?
One of the most puzzling questions concerning TSEs is the identity and
function of the infectious agent associated with the diseases. The answer must
account for the TSEs being infectious, genetic, and sporadic diseases, and also the
species barriers and strains that exist.
The TSE infectious agent has the biological properties of a virus but its
chemical properties are not typical of most viruses. Typical of a virus are the
barriers to interspecies transmission and the strains that exist. However, the
agent has been found to be resistant to chemical denaturants and treatments that
destroy most normal viruses. After years of searching, no conventional agent or
TSE-specific nucleic acid has been found. The infectious agent of the TSEs is
certainly unconventional but many do not believe it is only protein, as such an
infectious agent is totally unprecedented. The evidence for PrPSc being a
necessary component of the infectious agent is strong.56 As mentioned earlier,
treatments that disrupt nucleic acids do not affect infectivity. PrPSC copurifies
with infectivity and cannot be separated from it. Extensive protease treatments
that degrade PrPsc eliminate infectivity. There is also a strong genetic linkage
between specific PrP mutations and TSEs in humans. Finally, PrP knockout mice
do not get scrapie. While this evidence ties PrPS c to infectivity, the involvement
of potential cofactors that purify with PrP can not be ruled out.57 These could
conceivably include any of the molecules found in PrP preparations such as small
RNAs or DNAs, glycosoaminoglycans, or heparins, for example.58-60 Proof of a
protein only infectious agent or any other theory has not been possible. Up to
now infectivity has only been created in an animal or cell culture and the
purification always leaves the question of some minor contaminant that could be
the agent. Absolute proof of the "protein only" theory requires de novo
formation of infectivity from purified peptide.
The protein only theory can explain all of the aspects of the TSEs
described above. A large portion of this thesis explains how PrPSC could be the
infectious agent of scrapie using results from a cell-free PrPC conversion system.
A cell-free PrPC conversion system
In the summer of 1993, a collaboration was initiated between the Lansbury
lab at MIT and the Caughey lab at Rocky Mountain Laboratories (RML), an NIH
laboratory in Hamilton, Montana. The purpose was to study the folding and
unfolding of PrPsc and the conversion of PrPC to PrPSc. Renaturation conditions
for PrPS c were discovered and the conversion of PrPC to the protease-resistant
form was demonstrated soon after. This conversion system made possible many
informative experiments that will be covered in the following chapters. Chapter
2 deals with the renaturation of PrPsc and the conversion of labeled PrPC to a
protease-resistant form. Chapter 3 is about the initial mechanistic studies
undertaken to determine how the conversion of PrPC to the protease-resistant
form takes place. Chapter 4 is about the study of the TSE species barriers using
the cell-free system. Finally, chapter 5 covers the use of the cell-free system to
mimic the passage of strain-specific information that is seen in vivo.
Figure 1. The sequence of prion protein in various mammals. HaPrP, hamster
PrP; MoPrP, mouse PrP; HuPrP, human PrP; BoPrP, bovine PrP; ShPrP, ovine
(sheep) PrP. Asn 181 and Asn 197 are glycosylated. A disulfide exists between
Cys 179 and Cys 214. Treatment of PrPSc with PK results in cleavage around
residue 90.
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Chapter 2
The cell-free conversion of hamster PrPC to the protease-resistant form
Formation of protease-resistant PrP is known to occur in scrapie-infected
animals and chronically scrapie-infected neuroblastoma cells. Previously, these
cells were the simplest system capable of converting PrP to the protease-resistant
form. To study the mechanism of the conversion of PrPC to PrPsc, a simpler
system was required that does not have the myriad of variables inherent in a
biological system. An in vivo system is useful in studying the biosynthesis of PrP,
but the intention was to concentrate on the chemistry of the protein itself as
much as possible. Development of a cell-free conversion system was the first
goal of the work at RML.
The renaturation of PrPSc as visualized by antibodies to PrP epitopes
It is assumed throughout this study that an undefined level of unfolding
must occur for a normally protease-resistant peptide sequence of PrPSc to become
protease-sensitive. Conditions that allowed denaturation of PrPsc (as judged by
loss of resistance to PK) and renaturation (as seen by the return of PK resistance)
after the denaturant was diluted were found. PrPsc at a concentration of about
one gg/gL was first treated in 2.5-3 M guanidine-HCI (GdnHC1),1 a chaotropic
salt. To get an accurate time zero point, a sample of PrPSc in the presence of 2.5
or 3 M GdnHCl was treated with PK to assay its resistance before any
renaturation could begin. PK is a very hardy enzyme that functions in extremes
of temperature, pH, and denaturant. The PrP was visualized through the use of
sodium dodecyl sulfate- polyacrylamide gel electrophoresis (SDS-PAGE) and
then an immunoblot protocol which initially used a polyclonal antibody to PrP
peptide 90-104. Immunoblotting with the PrP 90-104 antibody, there was trace or
no PK resistance in the presence of 3 M GdnHC1. The PrPsc in 2.5 or 3 M
GdnHC1 was then diluted to 0.75 M with a Tris-HC1, NaCl (TN) solution. This
mixture was allowed to incubate at 370 C for between 2 minutes and 2 days and
then the PK resistance was determined. Some return of PK resistance in the
PrPSC was seen in as little as 2 minutes before the addition of PK and more was
seen after 2 days. Of course the PK needs time to hydrolyze the PrP and
renaturation in the 2 minute samples can be occurring as this happens, which
emphasizes the need for the time zero point.
To better define the effects of various concentrations of GdnHCl on the
protease-resistance of PrPS c, multiple antibodies were used in immunoblot
analyses of PrPsc subjected to these treatments. Also, to simplify the analysis of
PrP bands seen in this type of experiment, PrPSc was treated with peptide N
glycosidase F (PNGase F) immediately prior to SDS-PAGE. PNGase F removes
N-linked sugars which account for some of the band multiplicity of PrP.
After PK and PNGase F treatment of PrPSc without any denaturant
present, a predominant 19 kDa band (Fig. 2.1, marked by the solid arrowhead)
was detected using antisera to PrP residues 90-104, 106-115 (3F4), 143-156, and
217-232 (lane 2). As expected, residues 90-232 were resistant to PK. Without
PNGase F treatment, additional larger bands were detected, which represent
glycosylated forms of the 19 kDa polypeptide (lane 8). When PrPS c was digested
with PK in the presence of 2.5 or 3 M GdnHC1, the detection of the 19 kDa,
PNGase F-treated band by all three antibodies was greatly reduced (lane 3).
Instead, a prominant 16 kDa band (open arrowheads) was observed using the
antisera to PrP 143-156 and 217-232, but not with the antisera to PrP 90-104 or
106-115 (lane 3). Similarly, in the samples not treated with PNGase F (lane 9),
little PrP was detected with the 90-104 or 106-115 antisera (lane 9, top panels), but
the 143-156 and 217-232 antiersa detected sets of bands that were -3 kDa smaller
than those generated by PK treatment in the absence of GdnHCI (compare lanes
8 and 9, lower panels). These results showed that the GdnHCI treatment made
an additional ~3 kDa of the PrPS c polypeptide backbone sensitive to PK. Because
the detection by 90-104 and 106-115 antiersa was reduced much more than the
detection by the 217-232 antibody, most of the additional mass was lost from the
N-terminus. The calculated molecular mass of residues 90-115 is 3210, so the
removal of these residues could alone could account for the additional mobility
in SDS-PAGE. However, there was a partial loss of detection by the 217-232
antibody (compare lanes 8 and 9, lower panel) indicating that part of this epitope
was also removed by PK. Thus, the major effect of treatment with 2.5-3 M
GdnHCI was to denature PrPsc from residue 90 to the vicinity of residue 115,
with a less pronounced unfolding of the 217-232 epitope at the C-terminus.
The recovery of PK-resistance upon dilution of the GdnHCI and
incubation is also shown in Fig. 2.1 [compare lanes 3 with 4 and 5 with 6
(deglycosylated samples) and lanes 9 with 10 and 11 with 12 (glycosylated
samples)]. The antisera to PrP residues 90-104 and 106-115 indicated an increase
in the 19 kDa unglycosylated band (solid arrowhead) and an increase in the
glycosylated bands as well. The antibodies to PrP 143-156 and 217-232 indicated
a decrease in the 16 kDa unglycosylated band and an increase in the 19 kDa
unglysocylated band. Analysis of the glycosylated species also showed an
upward shift of ~3 kDa in the PK-resistant bands, giving a set of bands similar in
size to the control samples that were treated with PK in the absence of GdnHC1.
The extent of renaturation of all of these epitopes was greater after the 2.5 M
GdnHCl treatment than the 3 M treatment. The recovery of the PK-resistance of
all epitopes tested indicated that the denaturing effect of 2.5 and 3 M GdnHCI on
PrPsc was partially reversible.
This system for renaturation appeared to be working well, so a lot of effort
further altering variables was not done. Incubation time and temperature were
tested and some other denaturants were used. Using higher temperatures was
counter productive because irreversible denaturation occurred in 0.75 M GdnHCl
at 500 C. No benefit was found in extending the time for refolding to occur. The
maximum refolding would occur in two days or less and was usually 75% or
higher based on comparisons with undenatured, PK-treated samples. Very little
renaturation occurred from 3.5 M GdnHCl and denaturation in 4 M or higher
GdnHC1 at 370 C was permanent (Fig. 2.2). A map of PrP (Fig. 2.3) summarizes
the PK cleavage that occurred in the presence of different concentrations of
GdnHC1. 2 M or higher guanidine thiocyanate (GdnSCN) at 37' C produced
irreversible denaturation but the effect of 1 M was reversible (Fig. 2.4). Note that
with all antibodies the effect of 1 M GdnSCN on PrPSc was almost identical to 3
M GdnHC1. 25% (v/v) or higher hexafluoroisopropanol (HFIP) also irreversibly
denatured PrPSc. The use of GdnSCN or other denaturing conditions was not
pursued further.
Cell-free conversion of hamster PrPC to the protease-resistant form
Some of the steps in the process of refolding portions of PrPsc to the PK-
resistant form may be occurring during the conversion of PrPC to PrPSc. For this
reason, conditions that allowed refolding of PrPSc were used to convert PrPC to
the protease-resistant form. A source of 35S labeled PrPC was available from
high expressing cell lines developed at RML. 35S-PrpC was purified by
immunoprecipitation using a PrP antibody on protein A sepharose beads. The
35S-PrPC was removed from the beads by eluting it in 3 M GdnHC1. The seed or
nucleus for conversion was 2.5-3 M GdnHCl pretreated PrPsc that had been
prepared from hamster brains earlier for use in renaturation experiments. The
PrPSC and 35S-PrPC were mixed and diluted to 0.75 M GdnHCl using TN solution
and incubated for two days at 370 C. The concentration of PrPSc in the
conversion reaction was about 0.25 gg/gL with the 35S-PrPC concentration about
50 fold less. PK was added and the products were run on SDS-PAGE and the 35S
visualized using fluorography. This procedure resulted in PK-resistant 35S-PrP
reduced by about 7 kDa compared to the labeled starting material. This
reduction would be expected after treating PrPsc with PK.
PrP dimers and PrP without a GPI anchor converted to the resistant form
For this initial study, two different forms of PrPC were used. One was
recombinant hamster PrPC expressed in mouse neuroblastoma cells. This was
composed of monomeric PrP of 30-40 kDa and a 60 kDa dimer (Fig. 2.5a). The
monomer form varied over this range because of different levels of
glycosylation. 2, 3 After incubation with PrPsc and treatment with PK, the
predominant band was at 24 kDa, but there was some higher molecular weight
material produced. A 24 kDa band also predominates when scrapie-infected
cells are treated with PK. Ultracentrifugation was used to separate the
monomeric and dimeric forms of this PrPC construct. The separated forms were
then used in similar conversion reactions (Fig. 2.5b). Both converted to resistant
forms during incubation and different migrations were observed in the
predominant bands after PK treatment. The variation might have been due to
covalent differences between monomer and dimer affecting the action of PK.
The other PrPC construct used was a hamster PrP with a stop codon at
position 231 which usually has the GPI anchor attached. Therefore this construct
lacked residue 231 and the GPI anchor. In normal cell processing, amino acids
232 through 254 are cleaved as the GPI anchor is added. The lack of residue 231
and GPI anchor in this construct are the only differences between it and wild
type hamster PrP. The predominant 24 kDa species of this PrPC was
unglycosylated with a smaller amount of a 28 kDa monoglycosylated form (Fig.
2.5c). When this PrPC was incubated with PrPSc and PK treated, the
predominant band was at 17 kDa, 7 kDa less than the starting material. Again
this was expected after limited protease digestion to about residue 90. As had
been seen in other scrapie-infected cell culture systems, the GPI anchor was not
required for protease-resistance and a similar 17 kDa product has resulted from
scrapie infection in cell culture.4
Controls of the cell-free conversion
Controls were needed to show that there was specificity in the conversion
of PrPC to the PK-resistant form. The reaction was done with no PrPSc present
and no conversion was seen (Fig 2.5). The reaction was treated with PK after a
two minute incubation instead of two days. Two minutes was not enough time
to see any conversion which demonstrated that the conversion occurred after
mixing and longer incubation. PrPSc was added that had been pretreated with 0,
3, and 6 M GdnHC1. 3 M treated PrPSc gave more conversion than 0 M, and 6 M
gave no detectable conversion. The exact GdnHCl pretreatment that maximized
the conversion varied between 2.5 and 3 M GdnHCI depending on the PrPSC
preparation used. Fig. 2.6 shows conversion after different GdnHCI and
GdnSCN pretreatments of the PrPsc. Here the 2.5 M GdnHCl pretreatment
allowed more efficient conversion than 0 or 3 M GdnHC1 pretreatment. 3.5 M
GdnHCI pretreatment yielded barely detectable conversion and 4 M prevented
all conversion. 1 M GdnSCN pretreatment allowed a small amount of
conversion, but 2 M prevented all conversion. The denaturing conditions that
prevented recovery of the PK-resistance of PrPsc also eliminated its ability to
convert PrPC to the resistant form. Finally, these controls showed that a PrPSC
preparation with some native structure was required for the conversion and that
it occurred during the two day incubation period.
Another control was done to show that 35S-PrPC was the only labeled
protein from the cells that would become PK-resistant after incubation with
PrPSc. This control was accomplished by adding a set number of 35S counts per
minute (cpm) of lysate proteins while otherwise running the reaction as usual.
The ratio of cpm of PrPC versus lysate was about 1:15. Even in the presence of
the lysate proteins, the only specific band seen was from a protein whose
migration was identical to protease-resistant PrP (Fig. 2.7). This control shows
that it is probably not a general occurrence for proteins to gain protease
resistance after incubation with PrPSC. It would have been unexpected for other
proteins to become PK-resistant as a general occurrence, as many proteins are not
becoming resistant in scrapie-infected animals. The lysate is a mixture of many
proteins and a weakness of this control is that if one specific other protein could
become resistant it might be present with too few counts to be detected after PK
treatment.
The final controls were to show that the protease-resistance seen was not
limited to PK, and that the conversion was specific to the addition of a PrPsc
preparation to the reaction and not any amyloid. To check the resistance to other
proteases, trypsin and chymotrypsin were simply substituted for PK. PK-
resistant 35S-PrP was also trypsin and chymotrypsin resistant (Fig. 2.8). The
ladder of bands seen after trypsin digest was the result of cleavages after Lys or
Arg. These cuts probably occurred in the more protease sensitive N-terminal
portion of the molecule. B-amyloid from an Alzheimer's patient was pretreated
with 0 M and 3 M GdnHCl and then substituted for PrPS c in the reaction.
Incubation with 19-amyloid did not result in any protease resistance (Fig. 2.8,
lanes 7-8). More than just amyloid structure is required for the conversion to
occur. An even better control than 9-amyloid is to use a different species PrPSC
and this experiment is discussed extensively in chapter 4.
Conversion experiments with tunicamycin treated PrPCs
Because the complexity of the pattern of 35S-labeled PK-resistant bands
generated was due to variation in the N-linked glycosylation of the PrPC
precursor, the conversion experiment was done with PrPC from cells treated with
tunicamycin, which prevents N-linked glycosylation. The Asn residues at
positions 181 and 197 are glycosylated during biosynthesis. The addition of
tunicamycin to cells expressing recombinant hamster PrPC after labeling
produced bands at 25 and about 50 kDa in SDS-PAGE, (Fig. 2.9) which represent
unglycosylated monomeric and dimeric forms. In the conversion reaction, the
tunicamycin-treated PrP yielded a major band at 19 kDa after treatment with PK.
This band migrated in SDS-PAGE similarly to the predominant form of the GPI-
construct, which is also unglycosylated, after treatment with PK. The difference
was probably due to the presence of the GPI anchor affecting migration. This is
evidence that glycosylation was not required to achieve protease-resistance in
this cell-free system.
Limitations of this cell-free conversion system
To show that this system is generating 35S-PrPSc, the production of new
infectivity needs to be demonstrated. Unfortunately, that was not possible using
this system because of the vast amount of infectivity present when the PrPSc was
added. Bioassays cannot measure infectivity precisely and to see a significant
difference between samples, there must be at least 100 or preferably 1000 fold
difference in titer. This reaction has an approximate 50 fold excess of PrPSc to
begin with, and any new infectivity would be insignificant.
The major protein ingredients in this reaction were PrPSC, 35S-PrpC, and
the antibody used to immunoprecipitate it. The presence of this antibody was
controlled for by the experiment showing no conversion without added PrPSc.
The PrPsc preparations used have impurities that can not be controlled for which
can include DNAs, RNAs, glycosaminoglycans (GAGs), etc. If a very minor
component of the PrPSC preparation is a cofactor in the conversion as has been
suggested,5, 6 these experiments can not rule that out.
What this in vitro conversion system means
The initial studies of this cell-free conversion system were published in
August, 1994.7 It was stated in the manuscript that these results did not prove a
"protein-only" hypothesis for TSEs, but press accounts of this paper overstated
the results. This study did show that barring contaminants in the PrPSC
preparation as potential cofactors, direct PrPC-PrPSc interactions are required to
convert PrPc to the protease-resistant form. Little mechanistic detail was learned
from the study, but the system can be used for that purpose (see chapter 3).
The value of a cell-free conversion system for PrPC had already been
recognized. Papers published by Prusiner and coworkers explain their frustrated
attempts to convert PrPC in vitro. In a 1992 attempt,8 they mixed MoPrPS c with
recombinant mouse/hamster PrPC that was converted to a resistant form in their
infected cells. They used 35S-PrpC or a specific antibody to their recombinant PrP
to detect new PK resistance after incubation at 370 C. They achieved no increase
in protease-resistance, but it is difficult to tell what the concentration of any of
the components was. Concentration is important in this system and too low a
PrPsc concentration could explain the failure. In a 1993 effort,9 researchers
denatured PrPSC and then unsuccessfully tried to recover infectivity. Their
typical treatment was 6 M GdnSCN, which is quite harsh compared to the
conditions reported here. Recently, the Prusiner lab was able to reproduce the in
vitro conversion described in this chapter10 . Depending on the actual mechanism
of renaturation, a seed of native PrPSc structure might be required for recovery of
infectivity. PrPC treated with as much as 6 M GdnHCl was converted to the
protease-resistant form with the conversion system presented here, and the seed
of PrPSc with PK-resistant structure was crucial to the conversion.
This system presented an opportunity to study the conversion of PrPC to a
PrPSc-like form without all the complications of an in vivo system and was
evidence that the conversion may be solely due to direct PrP-PrP interactions.
This direct interaction is the essence of "protein-only" theories which state that
the infectious agent is only PrPsc that replicates itself in a new host. The system
allows a detailed look at the mechanism of the conversion and other biological
questions of the TSEs to be addressed.
Figure 2.1 Partial reversible unfolding of PrPSC in 2.5 and 3 M GdnHC1. Aliquots
of PrPSc were treated with PK in the designated concentration of GdnHC1
(renaturation = 0) or after four fold dilution and incubation for 1 d (renaturation
= 1 d) and further dilution prior to PK treatment. Control samples were not
treated with PK (lanes 1 and 7) or treated with PK without GdnHCl treatment
(lanes 2 and 8). The two columns of panels represent identically treated sets of
samples except for the use of PNGase F to deglycosylate the PrP samples
immediately prior to SDS-PAGE in the left column (lanes 1-6).
In lanes 3 and 5 in the a143-156 panel, the faint 27-30 kDa bands indicated that
the PNGase F was not always completely effective. Molecular weight markers
are indicated at the right in kilodaltons.
Figure 2.2 At high GdnHC1 concentration, unfolding of PrPSc was not reversible.
Multiple antibody analysis of GdnHCl- and PK-treated PrPsc was performed as
described for Fig. 2.1 except that the designated (higher) GdnHCl concentrations
were used in the initial unfolding pretreatment. The "renatured" samples were
diluted to 0.75 M GdnHCl and incubated for the designated time. The amount of
PK-resistance seen after 2 minutes was not always as much as shown. Control
PrPsc in lanes 1 and 2 was treated with PK (+) or not treated (-) without prior
exposure to GdnHC1. Molecular weight markers are indicated at the left in
kilodaltons.
Figure 2.3 Schematic depiction of PrP sequence, indicating PK-resistance of
PrPSc under various denaturing and renatured conditions. The bars at the top
represent PrP and the epitopes of the antibodies used in this study. The PK-
resistant regions are approximated based on a combination of their reactivities
with the antibodies and their sizes on the SDS-PAGE gels shown in Figs. 2.1 and
2.2. Where the termini are approximate, the borders are shown with jagged lines.
With no GdnHCl present, PK cleaves PrPsc to about residue 90. In 3 M GdnHC1,
PK eliminated most of the signal by the 90-104 and 106-115 antibodies, so the
majority of N-terminal cleavage was at least to 115. Based on the loss of the 217-
232 antibody signal, some proteolysis into its epitope at the C-terminus also
occurred. Upon treatment by PK in 3.5 M GdnHC1, and also after attempted
renaturation by dilution to 0.75 M GdnHC1, a small amount of PrP was detected
by the 143-156 and 217-232 antibodies, both reduced in mass by -3 kDa from
normal PrP. This portion of PrP indicated by the hatched area in 3.5 M GdnHCl
and the solid area in 3 M GdnHCl seemed to be the most resistant to
denaturation (the 16 kDa protease-resistant peptide core). 4 M GdnHCl
irreversibly eliminated all detectable PrP after PK treatment.
Figure 2.4 Partial unfolding of PrPsc was reversible from 1 M, but not Ž2 M
GdnSCN. GdnSCN was substituted for GdnHCl in the unfolding/refolding
procedures described in Fig. 2.1. The PK treatment was omitted in lane 1 (only).
Note that 2 M or higher GdnSCN inhibited the ability of PK to digest PrPSC (lanes
6, 9, and 12). To renature, GdnSCN was diluted to 0.75 M and the samples
incubated for 2' or 2 days before further dilution and treatment with PK. Note
that after dilution of GdnSCN from 2, 3, or 4 M, PK was able to digest all PrP and
no resistant material was seen after 2 days of incubation. Molecular weight
markers are indicated at the left in kilodaltons.
Figure 2.5 Conversion of 35S-PrpC to PK-resistant forms in the presence of PrPSc.
a, SDS-PAGE fluorography of 35S-PrPC with or without PrPS c. The 35S-PrpC was
recombinant hamster PrP expressed in mouse neuroblastoma cells. Lanes 2-10
contained 7 times more 35S PrPC than the non PK treated lane 1. GdnHCl
pretreatment refers to the concentration of GdnHCl the PrPSc was treated in
before mixing with the 35S-PrPC. Lanes 11 and 12 were immunoblots of PK-
treated PrPsc from neuroblastoma cells (NB) and scrapie-infected hamster brain
(Br). Lane 13 was an immunoblot of non PK-treated PrPS c from hamster brain.
b, Separated monomer and dimer from the 35S-PrpC used in a. 30-40k stands for
the 30-40 kDa monomeric PrP and 60k stands for the 60 kDa PrP dimer present as
this cell line expresses PrPC. c, The same as a except that a mutated PrPC with a
stop codon at residue 231 was substituted. This construct lacked the GPI anchor
and was expressed in mouse fibroblasts. Molecular weight markers are shown in
kilodaltons at the left.
Figure 2.6 Conversion of 35S-PrpC to the PK-resistant form using PrPSc
pretreated with GdnHCI and GdnSCN. The 35S-PrPC used here was the GPI-
construct that has been described in Fig. 2.5c. Lanes 1-10 contained 40,000 cpm of
35S-PrpC treated with PK after incubation with 2 jig of PrPSC pretreated at the
indicated condition. Lane 11 contained 10,000 cpm of untreated 35S-PrpC that
was used as substrate in the reaction. Lane 1 is the product of the conversion of
35S-PrPC with PrPSC in the absence of GdnHC1. Phosphorimager analysis
indicated that the ratio of 35S contained in the PK-resistant conversion products
(> 17 kDa) in lanes 1-4 was 1:2:6:2, respectively. Molecular weight markers are
indicated at the right in kDa.
Figure 2.7 Specificity of the conversion of PrPC to PK-resistant forms in the
presence of PrPsc. 35S-labeled fibroblast cell lysate proteins "lys" were tested in
the conditions used for the conversion of PrPC. The PrPC used here was the GPI-
construct mentioned in 2.5c. a, Combinations of PrPSc, PrPc, and "lys" were
tested for conversion to a PK-resistant form. "Inc. time" refers to the amount of
time the mixture was incubated at 370 C. The ratio of 35 S in PrPC to lysate
proteins was approximately 1:15. b, Same as a but the samples were treated with
PK except for lane 1. Equivalent proportions of the reaction mixtures were
represented in a and b, but the fluorographic exposure times for a (all lanes), b
(lanes 1-9) and b (lanes 10 and 11) were 2, 12, and 48 hours respectively to best
show the bands of interest. To show that PK has worked significantly, lanes bl
and a2 are the same except bl has been exposed 6 times longer. The asterisk
marks the 17 kDa PK-resistant band that resulted from incubation with PrPSC
even in the presence of the lysate proteins. Molecular weights are indicated at
the right in kilodaltons.
Figure 2.8 The 35S-PrP product of the conversion reaction was resistant to other
proteases and could not be formed using JR-amyloid as a seed. After a two
minute incubation, the 35S-PrPC GPI- was not resistant to any protease after
adding PrPsc (P) or f-amyloid (b) (lanes 1-4, top panel). Lanes 5-6 were
duplicates of the conversion using PrPSc and treated with PK. Lane 7 and 8 were
PrPC incubated with f9-amyloid that was pretreated with 0 or 3 M GdnHC1
respectively. PK treatment was subsequently performed after the conversion
reaction. Lanes 9 and 10 used treatment with chymotrypsin instead of PK after
the conversion reaction, but 10 was in the presence of 200 mM CaC12, which
improves the activity of chymotrypsin. Lane 11 has been treated with trypsin
instead of PK after the conversion reaction. The bottom panel showed the
samples without a protease treatment. Molecular weights are indicated at the left
in kilodaltons.
Figure 2.9 Conversion of unglycosylated PrPC to PK-resistant forms. Lanes 1-4
include the construct used in 2.5a with or without a treatment of 15 jtg/mL
tunicamycin during the labeling process. Lanes 3 and 4 were PK treated after a
two day incubation with PrPSc. Lane 5 used the construct used in 2.4c and is
shown after two day incubation and PK treatment for comparison. The PrPC
GPI- construct yielded a prominent band at 17 kDa and the unglycosylated PrP
in lane 4 yields a 19 kDa band. The difference is due to the absence of the GPI
anchor. Lanes 1 and 2 contained 7 times the counts as shown in the other lanes.
Molecular weight markers are shown at the right in kilodaltons.
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Experimental
Purification of PrPSc
The PrPSc source was brains of hamsters that had been inoculated with
263K scrapie and were showing signs of the disease. The preparation used was
based on the procedure of Bolton et al.11 Brains from scrapie-infected animals
were thawed in phosphate buffered saline (PBS)(10 mM Na2HPO4.7H 20, 10 mM
NaH2PO 4-H20, and 130 mM NaC1, pH=6.9) and rinsed three times to eliminate
most of the blood. 10% (w/v) sodium N-lauroylsarcosate in TEND (10 mM
TrisHC1, 1 mM EDTA, 130 mM NaC1, and 1 mM DTT, pH=8.3) was added to the
brains to give a 10% (w/v) solution. The brains were then homogenized and this
10% homogenate solution was put into centrifuge tubes in a Beckman TI 50.2
rotor and spun at 15K RPM at 4' C for 30 minutes. The supernatant was then
transferred to new tubes and spun at 38K RPM at 40 C for 2.5 hours in the 50.2
rotor. The supernatant was discarded and the pellets were combined. The
pellets were rinsed three times with 10% NaCl and 1% sulfobetaine 3-14 (SB) in
TEND. The combined pellets were then dounce homogenized in 10% NaCl and
1% (w/v) SB in TEND and added to the 50.2 rotor and spun at 45K RPM for 90
minutes at 200 C. Next the supernatant was discarded and the pellet washed
with TMCS (10 mM Tris, 5 mM MgC12' 5 mM CaC12, and 100 mM NaCl, pH=7.4).
The pellet was dounce homogenized in TMCS and DNAse (to 20 gtg/mL) and
RNAse (to 100 gg/mL) were added. This mixture was gently agitated overnight
at 40 C. To this solution was added EDTA to 20 mM, NaCi to 10%, and SB to 1%
(w/v). This solution was layered above a cushion of 1 M sucrose, 100 mM NaC1,
and 0.5% (w/v) SB and spun at 45K RPM for 90 minutes at 200 C. The
supernatant was discarded and the pellet rinsed three times with 1% SB in PBS
and then sonicated into 10% NaC1, 1% SB, in TEND in a microcentrifuge tube.
This was spun at 75K RPM for 10 minutes at 200 C in a Beckman TLA 100.1 rotor.
The supernatant was discarded and the pellet sonicated into distilled water and
centrifuged as just stated. Finally, that supernatant was discarded and the pellet
sonicated into 1% SB in PBS. PrPS c was used directly from the 1% SB in PBS
solution.
A 20% acrylamide gel (Pharmacia LKB Phast system) was run and silver
stained to determine the purity of a preparation. A BCA protein assay (Pierce)
was performed to estimate the total protein content and then immunoblots were
performed to confirm the quantity and quality of the PrPSc
Denaturation of HaPrPSC
To denature HaPrPSc, it was treated so the final concentration was about 1
mg/mL and the denaturant was the desired concentration. The solution was
incubated at 370 C for at least 1 hour, but not more than 24 hours. To assess the
extent of denaturation (get a time zero point), the PrPSc solution was diluted with
19 volumes of the same concentration of denaturant, which lowered the PrPSc
concentration to about 50 gpg/mL. It was then treated with 50 gg/mL PK directly
in the various denaturing conditions for one hour and the sample visualized
using SDS-PAGE as stated below.
Renaturation of HaPrPSC to a HaPrPSc-like form
To renature HaPrPsc to a HaPrPSc-like form, the denatured PrP solution
was diluted with three volumes of TN (10 mM TrisHCl and 100 mM NaC1,
pH=7.4 at room temperature) and allowed to incubate at 370 C for between two
minutes and two days. To test for the amount of renaturation that occurred, the
PrP solution was further diluted with four additional volumes of TN and then
treated with PK at a concentration of 50 jig/mL for one hour at 370 C. To inhibit
PK, Pefabloc was added to 0.1 mM and the solution let stand for five minutes.
SDS-PAGE sample buffer was added (1 mM EDTA, 6% urea (w/v), 5% SDS
(w/v), .05% bromophenol blue (w/v), 4% B-mercaptoethanol (v/v), and 10 mM
TrisHC1, pH=8.3) and the samples boiled for five minutes before performing
SDS-PAGE. SDS-PAGE was performed using 1 or 1.5 mm 14% acrylamide gels
(NOVEX) or 20% acrylamide gels (Pharmacia LKB Phast system). PrP was
visualized using an immunoblot procedure. This consisted of several steps: 1.
Proteins were transferred to an Immobilon-P transfer membrane (Millipore)
using a Milliblot SDE semi-dry transfer system (Millipore). 2. An antibody to a
peptide of HaPrP from rabbit serum was added to the membrane and allowed to
bind. 3. An anti-rabbit Ig, horseradish peroxidase linked whole antibody
(Amersham) was added and allowed to bind with the first antibody. 4. ECL
Western blotting reagents (Amersham) were added and the signal was visualized
on X-ray film. Note: Distortion of SDS-PAGE may occur if the GdnHC1 is not
diluted to <30 mM in the SDS-PAGE sample.
PNGase F treatment of denatured and renatured PrPSc
PrPsc was treated with PNGase F (New England Biolabs) after the final
methanol precipitation, after all other manipulations of the denaturing and
renaturing treatment were finished. The PrPsc methanol precipitate was taken
up in 20 gL of 88% formic acid and after 10 minutes on ice, rotary evaporated to
dryness. 20 gL of water, SDS (to 0.5% w/v), and 2-mercaptoethanol (to 1% w/v)
were added and the sample was boiled for 5 minutes. NP-40 to 1% (v/v) and 10
gL of sodium phosphate buffer were added. 2 gL of the supplied enzyme
solution were added and incubated at 370 C overnight. Sample buffer was added
to the solution and SDS-PAGE performed as before.
35 S-Labeling and Purification of PrPc
The PrPC converted in the cell-free reaction was 35S-labeled and
immunoprecipitated in the following manner. A 25 cm 2 flask of two-thirds to
three-fourths confluent cells was used and first washed 3 times with PBBS. For
one hour at 370 C the cells were preincubated with 1.5 mL Met/Cys deficient
growth medium. Note: methionine and cysteine are each at 0.1X normal
concentration in RPMI medium. 1 mCi 35S-Expre 35S35S label (NEN #Neg-072)
was added and incubated for 90 minutes at 370 C. The cells were then rinsed 3
times with cold PBBS and then lysed. The lysing buffer used was 1 mL of 0.5%
(w/v) Triton X-100, 0.5% (w/v) sodium deoxycholate, 5 mM TrisHCI pH 7.4 at 40
C, 150 mM NaCl, and 5 mM EDTA. Cell nuclei and debris was spun out by
centrifuging at 1000g for 5 minutes at 40 C. 4 volumes of methanol (-200 C) were
then added to the supernatant and left at -200 C for an hour to precipitate. A 15
minute spin at 2500g was used to remove the precipitate. The precipitate was
sonicated into 1 mL DLPC buffer as described in Borchelt et al.12 3 gL of 3F4
ascites was added and left at 40 C overnight. 30 gL of 10% (w/v) protein A
sepharose beads were added and gently agitated at 40 C for one hour. The
protein A sepharose beads were then washed one time with 1 mL DLPC, twice
with TN-1% N-lauroylsarcosine, and finally once with water. Residual liquid
was drawn off with a Hamilton narrow bore syringe. PrP was eluted with 25 gL
of 3-7.5 M GdnHC1. The beads were then gently agitated for 10 minutes at 370 C
and the eluate drawn off. This elution step was repeated. The first elution
typically had more counts per minute than the second but often it contained
enough to be useful. The eluted protein was used directly in the conversion
reaction. The labeled PrP was scintillation counted to determine the amount of
labeling. To purify tunicamycin treated PrP, 15 pg/mL tunicamycin was added
to the cells as the 35S was added and then immunoprecipitated in the same way.
Conversion of 35S-PrPC to the protease-resistant form
To convert the 35S-labeled PrPC to the protease-resistant form, PrPSC was
denatured in 2.5-3 M GdnHCl and then mixed with the labeled PrPC. A solution
of 2 gg/giL PrPsc was mixed with an equal volume of 5-6 M GdnHCl and then
incubated at 370 C for as little as 1 hour, but not more than 24 hours. Equal
volumes of denatured PrPsc and the labeled PrPC solutions were mixed and then
diluted to 0.75 M GdnHCl using TN (130 mM NaC1, 50 mM TrisHC1, pH=7.4 at
room temperature). Mixing was done so that PrPSc was never in more than the
desired pretreatment GdnHCl concentration. The solution was then incubated at
370 C for at least 16 hours.
The PK-resistance of the labeled PrP was then tested after further dilution
with TN by treating with 50 jgg/mL of PK for one hour at 370 C. Trypsin and
chymotrypsin at 50 gg/mL for one hour were also substituted for PK. PK was
inhibited using Pefabloc. 20 iRg of thyroglobulin as a carrier protein was added
and the samples were precipitated in four volumes of methanol at -200 C. The
resulting pellet was boiled in sample buffer and run on SDS-PAGE (14%
acrylamide gel). The 35S was visualized by soaking the gel in Entensify
autoradiography enhancer (DuPont), drying the gel, and exposing to X-ray film.
A typical reaction was:
2 gL of 1 mg/mL HaPrPSc in 3 M GdnHC1
2 gL HaPrPc with 30,000 cpm/gL in 3 M GdnHCl
12 RL TN
This was briefly sonicated and incubated. It was then diluted with 64 tL
TN and 4 gtL of 1 mg/mL PK was added. After an hour of incubation at 370 C, 20
p.L of 5X Pefabloc, 4 gL of 5 mg/mL thyroglobulin, and 4 volumes of methanol
were added. After an hour at -200 C, the tube was spun for 15 minutes at 15K
RPM in a Beckman microcentrifuge. The pellet was sonicated and boiled into 20
gL of the 1X urea sample buffer used above and run on SDS-PAGE.
Isolation of PrPC monomer and dimer from D4 cells
To isolate monomer, a 25 cm2 flask of D4 cells was first labeled as
previously mentioned. The cells were washed three times in PBBS and 1 mL of
PBBS was added along with 9 giL of phosphatidylinositol-specific phospholipase
C (PIPLC) (ICN) that was [0.1 u/jiL]. The cells were then incubated for 20
minutes with occasional rocking. The supernatant was removed and spun at
1000 RPM for 5 minutes in a JS 4.2 Beckman rotor. The supernatant was then
immunoprecipitated directly with 3F4 as previously mentioned.
To isolate the PrPC dimer, D4 cells were rinsed three times in cold PBBS.
They were lysed with 1 mL of lysing buffer as stated above. Cell debris was
removed by spinning at 1500 RPM for 5 minutes in a JS 4.2 Beckman rotor. The
supernatant was then layered over a 5% sucrose pad and spun at 90K RPM for 45
minutes in a TL100.3 Beckman rotor. The pellet was then sonicated into 1 mL of
DLPC and immunoprecipitated using 3F4 as mentioned above.
Conversion to the protease-resistant form in the presence of lysate proteins
The conditions used were identical to those mentioned above except for
the addition of labeled proteins that remained in the cell lysate after
immunoprecipitation. In this instance the lysate proteins were treated in 3 M
GdnHCI before mixing with PrPsc and labeled PrPC and then dilution,
incubation, etc. The amount added was based on the number of counts in the
lysate. Typically, 60,000 cpm of 35S in PrPC and 1,000,000 cpm in lysate proteins
were added.
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Chapter 3
Aggregates of PrPsc induce the cell-free conversion of PrPC to the protease-
resistant state
The inability to separate PrPSC and scrapie infectivity has made PrPSC the
prime candidate as the infectious agent.1-3 Supporting this idea are observations
from chapter 2 that PrPC will convert to the PK-resistant form when incubated
with preexisting PrPSC in a cell-free system. As mentioned in the last chapter, it
is not known yet whether new scrapie infectivity is generated upon conversion of
PrPC to these PK-resistant forms. The cell-free system was next used to probe
the mechanism of the conversion of PrPC to PrPs c . If PrPsc is all or part of the
infectious agent then this conversion is central to the infection process.
Any mechanistic model for PrPSC formation must address two questions
regarding this conversion reaction. First, what catalyzes the PrPC-to-PrPSc
conversion (the "converting activity")? According to the heterodimer/unfolding
model, the catalyst (PrPSc) is a monomeric conformational isomer of PrP that
catalyzes the conformational change via a PrPC-PrPSc heterodimer. 3-5
Alternatively, the seeded polymerization or nucleation model holds that the
catalyst is an ordered multimeric aggregate of PrP (PrPsc) which acts as a nucleus
for polymerization of PrP.6' 7 Second, what is the rate determining step in the
PrPC-to-PrPSc conversion? The heterodimer/unfolding model holds that the rate
determining step is a conformational change. In the nucleation model the rate
determining step is the formation of a multimeric seed of PrPSc which directs
further PrP polymerization. TSE infection would then be the transfer of
preformed PrPSC nuclei which instigate conversion in the new host. Attempts to
determine the mechanism of PrPSc formation are complicated by the fact that the
reaction itself and the physical state of PrPSc is difficult to monitor in vivo.
However, the in vitro system described above allows more direct characterization
of the species capable of inducing the conversion of PrPC to PrPSc-like protease-
resistant forms. This chapter describes experiments assessing the concentration
dependence of the reactants in the conversion reaction and the size of the
molecular species associated with converting activity by sedimentation and
ultrafiltration analysis.
Concentration-dependence of the cell-free conversion of 35S-PrPC to the protease resistant
form.
The extent of conversion of 35S-PrpC to protease-resistant, PrPSc-like
species was followed as a function of time and the amount of PrPSc added to the
reaction mixture (Figs. 3.1a,b). In this reaction, 35S-PrPC immunoprecipitated
from uninfected fibroblast cells was mixed with scrapie brain-derived PrPSC in
2.5 M GdnHCl and then diluted to 0.75 M GdnHCl to initiate the conversion
reaction. After the incubation period, the products of the reaction were treated
with PK to test for the conversion of 35S-PrPC to PK-resistant forms. For
quantitative comparisons, "conversion" was defined as the formation of 17-21-
kDa PK-resistant 35S-PrP since these were of the size expected of PK-digested
PrPSC derived from this type of PrPC precursor, i.e., 6-7 kDa lower in molecular
weight than the full-length 24-28 kDa 35S-PrPC precursor (e.g., see Fig. 3.3a).
Fig. 3.1b illustrates the increase in conversion as either the initial PrPSc or
incubation period were increased. The extent of conversion at 22 hours was
determined over a wider range of PrPsc concentrations (Fig. 3.2c). Increasing
PrPSc concentration always increased the extent of conversion although at high
PrPsc concentration (> ca. 100gg/mL), the concentration-dependence was less
marked. At PrPS c concentrations from 5-62 Rtg/mL, a plot of % conversion
versus initial PrPSc concentration was essentially linear. Extrapolation of such a
plot to % conversion =0 resulted in a non-zero x-intercept (ca. 5.1 gg/mL, 150
nM), providing evidence that a threshold concentration of PrPsc was required for
the existence of converting activity. The threshold concentration was also
supported by the fact that conversions attempted with PrPsc concentrations less
than 5 gg/mL gave no detectable product (data not shown). The value of the
apparent threshold concentration reflects the fact that the in vitro conversion
reaction was conducted in the presence of GdnHC1 and, thus, may be different
(presumably lower) in the absence of GdnHC1. The dependence of the total
conversion at 22 hours on 35S-PrPC concentration was also determined (Fig. 3.1e).
At a constant PrPS c concentration (125 gg/mL), the formation of 35S-labeled
conversion product was directly dependent on the initial 35S-PrPC concentration.
Extrapolation to 0% conversion demonstrated no threshold concentration. It is
important to note that, due to technical obstacles, the 35S-PrPC concentration
range examined was ca. 1% of the PrPSC concentration range tested in Fig. 3.1b
(see Experimental section).
Sedimentation properties of the converting activity
In chapter 2 it was stated that pretreatment of PrPS c with 2.5-3M GdnHC1
enhances the converting activity. Such GdnHCl treatments are also known to
disaggregate PrPSc.8 9 To determine if converting activity was associated with
an effectively solubilized PrPsc fraction I or a residual PrPSC aggregate, the
sedimentation properties of the converting activity was analyzed in the presence
1 Treatments with GdnHCl can alter the biochemical properties (i.e. PK-resistance and tendency to
aggregate) of PrPS that are usually used to define PrPS and distinguish it from PrPC. Nonetheless, to
define the origin of samples derived from PrPSc preparations, they will continue to be refered to as PrPSC
with the acknowledgement that the PrP in these samples might no longer have the defining properties of
PrPSc.
of GdnHC1. PrPsc pretreated with 3 M GdnHC1 was centrifuged under
conditions predicted to pellet 90% of particles of S20,w = 12 (based on
calculations described in Experimental section). The pellet and supernatant
fractions were tested for converting activity (Fig. 3.2a) and analyzed for PrP
content (without PK treatment) by immunoblotting (Fig. 3.2b). The vast excess of
PrPSc over PrPC in the reaction dictates that the PrP detected by immunoblot was
derived predominantly from PrPSC. A majority of the PrP was found in the
supematant, but converting activity was found only in the pellet. This indicated
that, although the 3 M GdnHCl treatment effectively solubilized more than half
of the original PrPsc preparation and increased the overall converting activity,
only sedimentable aggregates had converting activity.
To further compare the sedimentation rates of converting activity and
GdnHCl-solubilized PrPsc, a series of sedimentation velocity centrifugations was
performed (Fig. 3.3). In this experiment, PrPSC pretreated in 2.5 M GdnHCl was
used because preliminary experiments with this particular PrPSC preparation
indicated that the converting activity was optimal with this pretreatment. The
sample was placed over a layer of 5% sucrose in 2.5 M GdnHCl and centrifuged
at various speeds. Fractions of the gradient were tested for converting activity
(Fig. 3.3a,d) and analyzed by immunoblotting for total PrP content (Fig. 3.3b).
With spins of 2000 and 8000 x g, a majority of the converting activity remained in
the top (T) fraction corresponding to the sample zone (Fig. 3.3a,d). A spin at
70,000 x g cleared >95% of converting activity from the sample zone (T).
Calculations based on the clearing factor (k) for this rotor speed and sample zone
radius estimated that 90% of particles of S20,w = 17 would be cleared from the
sample zone under these conditions. A 234,000 x g spin cleared all detectable
converting activity from both the sample zone and middle (M) fractions. At this
speed, > 90% of particles of S20,w > 5 would be cleared from the sample zone. In
contrast to the converting activity, at least half of the PrP detected by
immunoblot remained in the top (sample) zone after these spins (Fig. 3.3b). This
confirmed that the converting activity was associated with sedimentable
aggregates rather than with the nonsedimenting PrPS c generated by the GdnHC1
treatment.
A set of single-subunit molecular weight standard proteins [lactalbumin
(14 kDa), trypsin inhibitor (20 kDa), carbonic anhydrase (30 kDa), ovalbumin (43
kDa), bovine serum albumin (67 kDa), and phosphorylase b (94 kDa); data not
shown] and thyroglobulin (669 kDa, with 335 kDa subunits; Fig. 3.3c) were
centrifuged at 70,000 and 234,000 x g in identical gradients containing 2.5 M
GdnHC1, but none sedimented through the gradient to the extent observed for
the converting activity at those centrifugal forces. Native thyroglobulin is 19S,
but the effect of 2.5 M GdnHC1 on the sedimentation properties of thyroglobulin
and the other protein molecular weight standards is not known. The
sedimentation behavior of blue dextran (2,000 kDa) was closest to that of the
converting activity, but the clearance of the blue dextran absorbance from the
sample (T) zone still was slower that of the converting activity [Figures 3.3a,c &
d] Thus, the detectable converting activity sedimented faster than the solubilized
PrP (monomeric MW = 25 - 30 kDa), other proteins up to 669 kDa (or 335 kDa if
thyroglobulin subunits are dissociated in 2.5 M GdnHC1) and 2,000-kDa blue
dextran.
To address the possibility that solubilization of converting activity might
be achieved at a different GdnHC1 concentration, PrPSC was treated in 0, 1.5, 2.0,
2.5 and 3.0 M GdnHCl and centrifuged at 234,000 x g in gradients formed with a
matching concentration of GdnHC1. In all cases, the detectable converting
activity was cleared completely from the sample zone and sedimented to the
bottom (B) and pellet (P) fractions (data not shown), indicating that the
converting activity was associated with aggregates regardless of the GdnHCI
concentration. GdnHCl concentrations greater than 3 M were not tested because,
as noted in chapter 2, converting activity is unstable at concentrations > 3.5 M
and not renaturable by subsequent dilution of the GdnHC1.
Sedimentation of PK-treated converting activity and PrPSC
Treatment of the PrPSC with PK results in the loss of approximately half of
the total PrP and removal of 67 N-terminal amino acids (6-7 kDa) from the
remaining PrPSc to generate a predominantly 27-30 kDa protein (PrP 27-30) (Fig.
3.4).10, 11 In addition, PK treatment degrades much of the large molecular weight
(>40 kDa) material that is observed by SDS-PAGE with typical PrPsc
preparations (PrP 27-30 is > 90% pure as determined by SDS-PAGE). Since PK
treatment does not eliminate the converting activity associated with PrPSc (see
chapter 5), PK pretreatment was tested to see whether it would allow the
converting activity to be more readily disaggregated by GdnHC1. PrP 27-30 was
treated with 2.5 M GdnHCI and subjected to a 234,000 x g gradient centrifugation
identical to that performed with the untreated PrPsc preparation. Analysis of the
converting activity in the gradient fractions indicated that it pelleted (Fig. 3.5a) as
it did prior to PK digestion (Figs. 3.2 & 3.3). Analysis of the total PrP by
immunoblot indicated that, in contrast to the situation with the untreated PrPSc,
none of the PrP 27-30 was effectively solubilized by the GdnHC1 (Fig. 3.5b). This
result suggested that PK digestion of PrPSC removed the PrP species that could be
effectively solubilized away from the PrPsc aggregates associated with
converting activity by 2.5 M GdnHC1.
Ultrafiltration of converting activity in GdnHCI
As another test of the size of molecular species associated with converting
activity, ultrafiltration was performed on PrPSC (not treated with PK) in 3 M
GdnHC1. PrPSc-derived PrP was retained by a filter with a nominal molecular
weight limit (NMWL) rating of 100 kDa (not shown) but passed through a 300
kDa NMWL filter (Fig. 3.6b). In contrast, the converting activity was retained by
the 300 kDa NMWL filter (Fig. 3.6a). Thus, the 300 kDa NMWL filter separated
the converting activity from the bulk of the solubilized PrPSC, providing
additional evidence that the converting activity is associated only with
aggregates larger than the dissociated PrP. Since the maximum pore size of the
300 kDa NMWL filter is estimated by the manufacturer to be 30 nm, the Stokes
radius of the inactive PrP that passed through this filter must be < 30 nm. The
Stokes radius of the converting activity must be larger than that of the PrPSc
without converting activity; however, one cannot definitively conclude that it is
greater than 30 nm because of possible polarization layer effects and the
likelihood that the average pore size of the filter is much lower than 30 nm.
Similar filtration experiments performed with filters with nominal
maximum pore sizes of 100-450 nm indicated that converting activity could pass
through the filters (data not shown). The passage of converting activity through
the 100 nm (maximum pore size) filter indicated that it can have a Stokes radius
of < 100 nm.
Ultrafiltration of PK-treated converting activity in GdnHCI
Ultrafiltration of PK-treated PrPSC in 3 M GdnHCl indicated that the
converting activity was retained by both 100- and 300-kDa NMWL filters as was
the case with the untreated PrPSc (Fig. 3.7a). In contrast to the untreated PrPS c,
little (<15%) of the PK-treated PrPsc passed through the 300 kDa NMWL filter
(Fig. 3.7b). This was consistent with the sedimentation analysis of PK-treated
PrPSC (Fig. 3.5b), which also indicated reduced solubilization by GdnHCl
compared to the untreated PrPSC.
PK-resistance and renaturation of PrPSc are associated with GdnHCl-insoluble
aggregates
Having detected converting activity only in the more aggregated PrPSc
fractions generated by filtration or centrifugation in 2.5-3 M GdnHC1, these same
fractions were tested for resistance to PK in GdnHC1. They were also tested for
the ability to recover PK resistance after dilution of the GdnHC1. This was done
very similarly to the procedure mentioned in chapter 2 using different antibodies
to PrP epitopes. In Fig. 3.8 samples of unfractioned, supernatant, and pelleted
PrPSc were immunoblotted without PK treatment to compare the amount of PrP
present. A 234,000 x g, 30 minute spin that should clear particles of S>5 divided
the PrP approximately in half (compare lanes 2 and 3). Samples of supernatant
material were treated with PK in the presence of 3 M GdnHCl and no PrP was
detected by any of the antibodies (lane 4). The protease resistance of the pelleted
material in the presence of 3 M GdnHCl was similar to the unfractioned material
(lane 6). Supernatant and pelleted fractions were then diluted to 0.75 M GdnHCl
and allowed to incubate overnight before treatment with PK. Again there was no
PK-resistant PrP visualized by any antibody from the supernatant fraction (lane
5). However, most of the PrPSc in the pellet recovered its PK-resistance
indicating that renaturation of this aggregated PrPSc had occurred (lane 7).
These results suggest that PrPsc must be aggregated to have protease resistance.
Association of converting activity with PrPSC aggregates
The cell-free reaction for converting PrPC to PK-resistant forms has made
it possible to begin characterizing the components and mechanism of the
converting activity under defined conditions. The dependence of conversion rate
on the amount of PrPsc in the reaction mixture establishes that a component of
the PrPSC preparation is involved in the rate-determining step. The sedimentation
and filtration of the converting activity indicated that it was associated with
aggregates that range in size from being at least several times larger than
solubilized PrP to macroscopic particles. The sedimentation and filtration data
provided complementary information about the sizes of species with converting
activity. The sedimentation rate of a particle is a function of both its size and
shape. Thus, one might argue that subtle differences in sedimentation of PrP
species could be explained by differences in conformation rather than
aggregation state and that converting activity is associated with a more compact,
rapidly sedimenting conformer. However, if this were the case, the more
compact conformer would also be expected to pass more readily through the
pores of an ultrafiltration membrane than a more extended conformer with a
larger Stoke's radius. The opposite result was observed, which is consistent only
with the converting activity being associated with an aggregate of larger mass
than the solubilized PrP. This conclusion was confirmed by the observation that
the detectable converting activity sediments faster than other molecules up to 50
times greater in molecular weight than monomeric PrP.
The nature and origin of the PrP without converting activity or protease-
resistance that was solubilized from the original PrPsc aggregate is not clear, but
GdnHCI-soluble subfractions of PrPsc have also been observed by other
investigators.8, 9 Since these PrP molecules appear to be more sensitive to PK
than the residual PrP 27-30 aggregate, they may be PrPC molecules that are
bound (normally or artifactually) to PrPsc without being fully integrated and
converted to PK-resistant state characterized by PrP 27-30. The stimulation of
converting activity by the GdnHCl treatments of PrPsc may be due to the
removal of these nonconverted PrP molecules which may be "abortive
complexes" that block access to active catalytic surfaces for the conversion
reaction. The presence of these GdnHCl soluble PrP molecules might also
contribute substantially to the PrPC precursor concentration once the GdnHCl is
diluted for the conversion reaction. However, this solubilization would have the
effect of greatly diluting the specific radioactivity of the PrPC, which would
likely diminish, rather than stimulate, the observed formation of PK-resistant 35S-
PrP conversion products. Another possibility for the increase in converting
activity is that GdnHCl solubilizes some cofactor that is needed for the
conversion.
Ramifications regarding models of PrPSc formation
Evidence on the sizes of species that contain converting activity is useful
in discriminating between various theories for the mechanism of PrPSC
formation. The observation that a wide range of PrP aggregates possess
converting activity is consistent with the nucleation model. As in the case of
amyloid formation, any aggregate larger than the critical nucleus would be a
competent seed for polymerization.7 The nucleus, which is defined as the least
stable intermediate along the aggregation pathway, must be an ordered
oligomer.
The observation of a threshold concentration for converting activity is also
consistent with the nucleation proposal, in which the converting activity is a seed
for the ordered aggregation of PrP. The threshold concentration may correspond
to the critical concentration which is observed for protein polymerization
processes known to occur via a nucleation-dependent mechanism (e.g.,
microtubule formation, flagellum formation, sickle cell fibril formation).12-15
Below the critical concentration, the predominant species is the monomer. The
nucleus is, by definition, the highest energy species along the polymerization
pathway and the smallest possible seed for polymerization.7 Since the nucleus is
almost completely dissociated below the critical concentration, one would not
expect to see conversion. However, above the critical concentration, the
predominant species are large aggregates, in equilibrium with the monomer. All
of these post-nucleus aggregates are, in theory, capable of seeding the
polymerization. The non first-order concentration dependence seen at high PrPSc
concentration may be due to ultrastructural effects, for example, fibril bundling,
which may occur in those concentration ranges. Bundling could decrease the
efficiency of the seed by blocking the active growth faces.7 The threshold
concentration observed (ca. 150 nM) may reflect the solubility of PrPsc under the
conditions of the in vitro conversion reaction (0.75 M GdnHC1). The solubility of
PrPsc under more physiological conditions would probably be lower.
In contrast, the present data are not consistent with the heterodimer
model, which postulates that the active species is a monomer. Although PrPsc is
usually isolated in rapidly sedimenting aggregates, the aggregation of PrPSC may
be largely an artifact of purification and that the active species is a PrPSc
monomer (or small oligomer) that dissociates as a discrete unit from the
aggregate.3 The cell-free conversion assay has given us the opportunity to
directly test for converting activity in subfractions of PrPSC preparations treated
with a wide range of conditions (from 0-3 M GdnHC1) with varying tendencies to
solubilize PrP from the preexisting PrPSC aggregate. In all cases, converting
activity was detected only in the aggregate fractions rather than in supernatants
or filtrates containing dissociated PrPSc. These data are inconsistent with the
idea that the active PrPsc species is solely a monomer or small oligomer. Finally,
the threshold concentration effect would not be expected of a monomeric species.
It is instructive to consider separately a heterotrimer model, which
postulates that the converting activity is a PrPsc dimer. The concentration-
dependence of dimer formation would be second-order, not first-order as
observed. In addition, a dissociating dimer could pass through the filter in
monomeric form and reassociate in the filtrate. A nondissociating dimer,
analogous to the dimeric form of CD2 which has recently been characterized, 16
would show a first-order concentration dependence, but not a threshold
concentration. A dimer with an extremely high association equilibrium constant
could produce a curve which may resemble the one seen in Fig. 3.1d, however, it
is clear from the sedimentation experiments that a PrPSC dimer is not the major
converting species. Nonetheless, these results cannot absolutely rule out the
possibility that small oligomers, such as dimers or trimers have some limited
(undetected) converting activity.
If PrPSC were active as a monomer, then this sizing data would require
that it be attached to a non-PrP molecule(s) or aggregate of much greater size to
account for its sedimentation and filtration properties. Although the complete
composition of these aggregates is not clear, silver stain and immunoblotting
analyses of fractions containing converting activity indicate that PrPSC is the
predominant protein component, especially after PK digestion (Fig. 3.4).17
Therefore, the particulate behavior of the converting activity is likely due to an
association with PrPSC aggregates rather than with PrPS c monomers bound to a
much larger mass of other molecules. These results do not rule out the
possibility that some non-PrP molecules have gone undetected or could be minor
constituents of the aggregates. This is especially plausible because of the vast
excess of PrPsc over 35S-PrPC in the present conversion reaction. For instance,
glycosaminoglycans and other possible ligands (e.g. pentraxins, chaperonins,
apolipoprotein E, NAC, nucleic acids) have been postulated to play roles in the
formation or stabilization of PrPSc. 18-21 These factors might be present and active
in the PrPSC preparations at substoichiometric levels as part of the conversion
mechanism. It can be concluded from the present study that any such factor
must co-purify with GdnHCl-resistant PrPSC aggregates and be resistant to PK.
Reconciling the properties of the in vitro converting activity with those of the scrapie
infectious agent
Given the hypothesis that the activity that induces PrPsc formation is the
infectious agent of scrapie, it is relevant to consider how the aggregated nature of
the in vitro converting activity compares to previous analyses of the size of the
scrapie agent. Many studies have indicated that scrapie and Creutzfeldt-Jakob
disease infectivity is associated with large sedimentable (>40 S) particles.
However, other analyses have indicated that much smaller sized particles can be
infectious. 22-24 For instance, scrapie associated fibrils (SAF) or prion rods are not
visible by electron microscopy in all infectious preparations (e.g. liposome
preparations). 22, 25 However, it is possible that the low concentrations of small
PrP aggregates required to nucleate polymerization might escape detection,
especially in liposomes. Furthermore, the increased infectivity of a liposome-
PrPSc suspension relative to a sample containing the same amount of PrP in the
form of amyloid fibrils 25 is consistent with the nucleation model in which smaller
PrP aggregates would have a higher converting activity per PrP molecule. It
must be emphasized that the nucleated polymerization model requires only that
the seed be ordered, not that it have the morphological properties of an amyloid
fibril. The sensitivity of the scrapie agent to inactivation by ionizing radiation is
consistent with the agent being a PrP dimer of ca. 55 kDa.23 However, it is also
consistent the agent being a substantially larger nucleus. Many oligomeric
enzymes have produced monomeric target sizes, indicating that energy transfer
between subunits need not occur and that the activity of each subunit can be
independent of the activity of its neighbors in the oligomer.26-28 Accordingly, if
the scrapie agent is an aggregate of PrP, the interpretation of the radiation target
size data will be complicated by the fact that a multimeric PrP seed may be
resistant to radiation damage of subunits that are not part of the growth face.
The observed target size of 55 kDa may reflect a growth face defined by two PrP
molecules within the context of a larger polymer.
Figure 3.1 The PrPSc- and time-dependence of the conversion reaction. a.
Converting activity. PK-resistant 35S-PrP species generated from the incubation
of 35S-PrPC with different concentrations (gtg/mL) of PrPsc for various lengths of
time (hr) as described for the conversion reaction in Experimental. The PrPC
used in this study lacks a GPI anchor and is predominantly unglycosylated (24
kDa), with a minority monoglycosylated (28 kDa) (see Fig. 3.3a, for example).
The bracket on the left and in subsequent figures indicates the PrPSc -like 17-21
kDa bands that were used in the quantitative comparisons described below. All
lanes represent reactions initiated with 60,000 cpm of 35S-PrPC. Molecular
weight markers are indicated at the right in kDa. b. Percent of 35S-PrPC
converted to 17-21 kDa PK-resistant species (mean + S.D. of triplicate
determinations) after incubation with designated PrPSc concentrations as a
function of incubation time (includes data shown in a). Only bracketed bands as
shown in A were counted as converted product using the Phosphorimager. c.
Percent conversion in 22 hr versus [PrPSC]. d. Expanded plot of linear region of
data in panel c showing a line fit by simple linear regression with an X-intercept
of 5.1 gg/mL (0.15 giM PrPSC, based on a molecular weight of 35 kDa). e. Plot of
the total 16-20 kDa conversion product versus initial [35S-PrPC ]. Semi-
quantitative immunoblotting was used to estimate the total PrPC as 10 ng/60,000
CPM. The [PrPSc] and incubation time were constant in these reactions at 125
gg/mL and 22 hours respectively. The percentage of the initial 35S-PrPC that was
converted was approximately 20% over the entire range tested.
Figure 3.2 Comparison of the converting activity in aggregated versus
solubilized PrPsc. a. Converting activity (as described in legend to Fig. 3.1a) in
aliquots of unseparated (total) PrPsc in 3 M GdnHCl or of pellet or supernatant
fractions of the same after centrifugation at 217,000 x g max. b. Immunoblot
showing relative total PrP content of same fractions used in the conversion
reaction in a. A polyclonal rabbit antiserum raised against a synthetic peptide
corresponding to hamster PrP residues 90-104 was used. Molecular weight
markers are indicated at the right in kDa.
Figure 3.3 Sedimentation analysis of GdnHCl treated converting activity and
PrPSC. a. Converting activity (as described in legend to Fig. 3.1a) in aliquots of
unfractionated (total) PrPs c in 2.5 M GdnHCl or top (T), middle (M), bottom (B),
and pellet (P) fractions (as indicated by diagram at left) after centrifugation at the
designated g force. One third of the 35S-PrPC used in each conversion reaction is
shown without PK digestion in the PrPC lane. Molecular weight markers are
indicated at the right in kDa. b. Immunoblot of the total PrP in fractions
described in a. c. Sedimentation of thyroglobulin (669 kDa total, 335 kDa
subunits) or blue dextran (2000 kDa) in 2.5 M GdnHC1 on identical gradients. d.
Clearance of the converting activity from the sample (T) zone after centrifugation
at the designated relative centrifugal forces (RCF). The ordinate is the percent
reduction in the 16-20 kDa PK-resistant 35S-labeled, PK-resistant PrP species
generated in the conversion reaction by aliquots of the T fractions as compared to
the total unfractionated PrPSc sample. The data points show the mean + range of
measurements from two independent experiments (including the one in panel a),
except in the case of the 2,000 x g spin which is from a single determination. For
comparison, the calculated S20,w values of particles that would be 90% cleared
from the sample zone under the conditions of each centrifugation are shown.
Figure 3.4 SDS-PAGE with silver staining of PrPsc before and after treatment
with PK as described in Experimental. The thin band seen just above 30 kDa in
the third lane was likely PK itself. The 1/5 dilution refers to a 5 fold decrease in
the protein concentration loaded onto the gel after PK treatment. Molecular
weight markers are indicated at the left in kDa.
Figure 3.5 Sedimentation of converting activity and PrPSc after PK treatment.
PrPSC was treated with PK as described in Experimental section, incubated at 1
mg/mL for 5 hr at 370 C in 3 M GdnHCl and fractionated at 234,000 x g max on a
gradient identical to those described in Fig. 3.3. a. Converting activity (as
described in the legend to Fig. 3.1a) in unfractionated (total) K-treated PrPSC in
2.5 M GdnHCl or top (T), middle (M), bottom (B), and pellet (P) fractions. One
third of the 35S-PrPC used in each conversion reaction is shown without PK
digestion in the PrPC lane. b. Immunoblot of the total PrP in fractions described
in a. Molecular weight markers are indicated at the right in kDa.
Figure 3.6 Ultrafiltration of PrPSc in 3 M GdnHCl and measurement of
converting activity. Filtrate and retentate fractions were obtained from a 300 kDa
NMWL filter as described in Experimental section. a. Converting activity in
equivalent aliquots of the retentate, filtrate and unfractionated sample (total). b.
Immunoblot of the total PrP in same fractions. Molecular weight markers are
indicated at the right in kDa.
Figure 3.7 Ultrafiltration of PK-treated PrPSC in 3 M GdnHCl and assessment of
converting activity. The PK-treated PrPSc described in Fig. 3.5 was incubated in 3
M GdnHCl at a concentration of 1 mg/mL and filtered as described in Fig. 3.6
except that 100 kDa NMWL filters were also used. a. Converting activity in
equivalent aliquots of the indicated fractions. One third of the 35S-PrPC used in
each conversion reaction is shown without PK digestion in the PrPC lane. b.
Immunoblot of the total PrP in same fractions. Molecular weight markers are
indicated at the right in kDa.
Figure 3.8 PK-resistance and refolding of soluble vs. aggregated fractions of
PrPSc. PrPSC in 3 M GdnHCl was fractionated by ultracentrifugation at 234,000 x
g as described in Experimental. Fractions are designated as whole or
unfractioned (w), supernatant (s), or pelleted (p). The first three lanes are to
compare the total amounts of PrP in each fraction without PK-treatment. The
supernatant and pellet fractions were treated with PK in 3 M GdnHC1
(renaturation time = 0) or diluted to 0.75 M and incubated for one day before
further dilution and treatment with PK as described in Experimental.
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Experimental
PrPSc
PrPSC was purified from the brains of hamsters infected with the 263K
strain of scrapie as described in chapter 2 and was sonicated into 0.5-1%
sulfobetaine 3-14 (SB) in phosphate buffered saline (20 mM sodium phosphate
and 130 mM NaC1, pH 7.4) and stored at -20' C prior to use.
In some experiments, PrPSC was treated with PK prior to fractionation as
follows. PrPsc at a concentration of 200 gg/mL in 10% (w/v) NaC1, 1% SB in
TEND (10 mM Tris-HC1, 1 mM EDTA, 1 mM DTT, and 130 mM NaC1, pH 8.3)
was treated with 25 gg/mL PK for 1 hr at 370 C. The reaction was stopped by
adding aprotinin, leupeptin, and Pefabloc to .01 AM, 1 AM, and 0.1 mM,
respectively. The PrPSC was centrifuged for 15 minutes at 12,000 x g at 40 C and
the supernatant removed. The pellet was sonicated into 0.1% N-lauroylsarcosine,
.01 AiM aprotinin, and 1 AM leupeptin. The PrPS c was centrifuged as before and
the pellet sonicated into 1% SB and PBS and stored at -200 C until use.
Conversion of PrPC
Conversion experiments were done very similarly to those for chapter 2. 2
jiL of fractions to be tested for converting activity were added to reactions.
Incubation times at 370 C ranged from 2-22 hours. Further dilution, PK treatment
and SDS-PAGE were performed as stated in chapter 2. Besides using
fluorography as mentioned in chapter 2, a Phosphorimager (Molecular
Dynamics) was used to quantify 35S in specific bands. The amount of converted
35S-PrP GPI- after PK treatment in the 17-21 kDa range was compared with
known quantities of 35S in non PK treated 35S-PrpC in the 24-28 kDa range. In
this way percent conversion efficiencies were calculated.
Centrifilgation of PrPsc
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For the simple centrifugation of GdnHCl-treated PrPSC (as in Fig. 3.3), 50
gL of PrPSC pretreated at 1 mg/mL in 3 M GdnHCl for 5 hr at 370 C was
centrifuged at 70,000 rpm for 50 min at 200 C in a Beckman TL100.1 rotor. The
supernatant was collected and the pellet was resuspended by cuphorn sonication
into 50 gL of fresh 3 M GdnHC1. Aliquots of each fraction were assayed for
converting activity in the cell-free conversion reaction described above and for
total PrP content by immunoblotting as described in chapter 2.
Sedimentation velocity gradients were performed by layering 20 p.L of a
given PrPsc preparation (preincubated at 370 C for 2-18 hr in 2.5 M GdnHC1) over
40 gL of a solution with identical GdnHCI concentration and 5% (w/v) sucrose in
a Beckman 7 x 20 mm polycarbonate centrifuge tube. The tubes were spun to
give the designated maximum g-force for 30 minutes at 200 C in a Beckman TLS
55 swinging bucket rotor using the slowest acceleration and deceleration settings.
The gradients were fractionated as shown in Fig. 3.4 and the pellet was sonicated
into an additional 20 giL of solution. Equal aliquots of the fractions were assayed
for converting activity and for total PrP content by immunoblotting. Molecular
weight standard proteins were dissolved in 2.5 M GdnHCl at approximately 1
mg/mL and fractionated on gradients exactly as was PrPSC. The concentrations
of the molecular weight standards in the fractions was determined by SDS-PAGE
with silver staining, except in the cases of thyroglobulin and blue dextran. The
latter two were too large to enter the SDS-PAGE gels so they were run on
separate gradients and their concentrations in the fractions were determined by
absorbance at 280 nm and 625 nm, respectively.
Estimation of sedimentation coefficients
The sedimentation coefficient (s in Svedberg units, S) of particles expected
to be 90% cleared from the sedimentation velocity gradient sample zones within
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the time of centrifugation (t in hr) was estimated using the following equation
from the Beckman centrifuge manual:
Sobs = k/t
where k is the clearing factor for the sample zone given by
k = 253303 In (rmax/rmin) / (RPM/1000)2
where rmax and rmin are the maximum and minimum radii, respectively, of the
sample zone within the spinning rotor and RPM is the revolutions per minute of
the rotor.
Estimates of the s20,w values for the particles was obtained from sobs using
equation (2) of Prusiner, et. al.29 to correct for the difference in density between
2.5 M GdnHCl and water. No correction for a difference in viscosity was made.
Ultrafiltration of PrPSC
Millipore Ultrafree-MC polysulfone membrane 100,000 and 300,000
NMWL filter units were used according to the manufacturer's instructions. PrPSc
to be filtered was first incubated in 3 M GdnHCI at 370 C at 1 mg/mL for 2-5 hr.
50 gL of the PrPsc solution was loaded onto the filter and then centrifuged at 1-
2,000 rpm until about half of the solution had been filtered. The retentate
fractions were then diluted back to 50 [tL with 3 M GdnHCI (the filtrates were left
neat) and 2 jiL of each was immediately added to a conversion reaction to assess
converting activity. Equivalent parts of each fraction were also diluted and
immunoblotted to determine the total PrP content. After an initial protease
treatment, PK-treated PrPsc was filtered and assayed identically to non-protease
treated PrPSc.
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Chapter 4
Species specificity in the cell-free conversion of PrPC to protease-resistant
forms: a model for the species barrier
The barrier to interspecies transmission is an important phenomenon
associated with the TSEs. If a specific interspecies transmission is possible, then a
large increase in the incubation time of the disease is usually observed. In some
cases, interspecies transmission is not observed. If an initial interspecies
transmission was possible, on subsequent passages of the agent into the same
species the barrier decreases. For instance, the incubation time of Chandler strain
mouse scrapie is about 120 days into mice and about 380 days into hamsters. 1' 2
In contrast, the incubation time of the 263K hamster strain into hamsters is about
60 days, but the disease is not transmitted to mice (no disease after a two year
observation period).3 Extended incubation time in one direction is observed and
a total barrier to disease in the other. Many other examples of such barriers have
been noted.
As mentioned in chapter 1, in 1985 cows began getting sick with a scrapie-
like disease in England. The disease, known as bovine spongiform
encephalopathy (BSE), grew to epidemic proportions. While not known for
certain, this outbreak may have originated as sheep scrapie. An endemic sheep
scrapie exists in England (and the U.S.) and sheep meat and bone meal had been
used as feed supplements for cattle for many years. In 1981, a solvent extraction
and superheated steam treatment of the meal was discontinued. One theory of
the origin of BSE is that eliminating these processing steps allowed sheep scrapie
to infect cows through the feed. The only firmly established method of BSE
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transmission to other cows has been through ingestion of contaminated meal.4, 5
The expense of dead cattle was not the only problem for the British cattle
industry. The fear of human susceptibility to BSE arose. The oral infection route
being established, could humans get BSE from eating infected beef? The answer
to that is a qualified yes. A new strain of CJD has been identified that is possibly
caused from BSE infection in humans.6 This new strain has different pathology
from other CJD strains and has PrP plaques that look similar to those seen in
kuru. The U.S. and Germany have banned the import of British beef since 1989
and 1990 respectively. Recently at least 22 other countries have also banned
British beef causing economic hardship to Britain's multibillion dollar cattle
industry. These bans will probably remain for some time as the risk of human
transmission is studied. British consumption of beef has understandably
declined sharply. The situation must be grave when even McDonald's
restaurants in Great Britain have stopped using British beef.
In 1988 the British government banned the use of ruminant-derived feed
supplements and now the number of new cases of BSE is declining. If there is no
other method of transmission then the number should continue to drop. It is not
known if BSE will become endemic to cattle the way scrapie is to sheep. Another
possibility is that BSE was endemic to cattle but that changes in rendering
allowed for the increased spread of the disease. Sheep scrapie has been a
controllable problem. It spreads from animal to animal in a flock or from mother
to unborn offspring. Sheep scrapie has been known for hundreds of years and
has not been seen to be infectious to man based on epidemiological studies.
The cell-free conversion system had an obvious application in determining
if the species barrier would apply in vitro. Not only can the cause of the barrier
be studied, but the question of human infection by BSE can be probed.
Conversion of MoPrPC to a resistant form by incubation with a MoPrPSc preparation
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All previous experiments used 263K HaPrPSc to convert different types of
HaPrPC to the protease-resistant form. Experiments were then done to see if
mouse PrP would work in this conversion system. To begin, a source of MoPrPsc
and 35S-MoPrPC was needed. MoPrPSC was purified from Chandler scrapie
infected mouse brains using the HaPrPSc purification procedure. A mouse cell
line that produced wild type MoPrPC was used as that source. The MoPrPC was
immunoprecipitated as HaPrPC had been except that a different antibody was
used.
For use in a conversion reaction, the MoPrPC was eluted from protein A
sepharose in 3 M GdnHCl and mixed with MoPrPS c that had been treated
overnight in 3 M GdnHC1. TN buffer was used to dilute the concentration of
GdnHCl to 0.75 M and the concentrations of proteins were the same as that used
for the hamster conversion. Protease-resistant PrP seemed to be produced
whether MoPrPSc was added or not. This protease-resistant material was also
present in 2 minute incubation samples. This result was reproducible and it was
concluded that 3 M GdnHC1 trapped MoPrPC in an "abortive conformation" that
the presence of MoPrPsc did not affect. No similar effect was ever seen using
HaPrPC. It is not known if that material would be infectious.
To get around this "abortive conformation" the MoPrPC was eluted in
higher concentrations of GdnHC1. Until the immunoprecipitated MoPrPC was
protease sensitive, experiments to convert it into a protease resistant form would
not work. Eluting the MoPrPC in 7.5 M GdnHC1 was effective in making it
properly PK sensitive. With that knowledge, the conversion experiment could be
attempted again. The MoPrPC in 7.5 M GdnHC1 was diluted with TN and then
the MoPrPSC in 3 M was added so it did not experience higher GdnHC1
concentration. The protein concentrations were reduced because of extra
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dilution to get to 0.75 M GdnHC1, but after a two day incubation at 370 C and PK
treatment, protease resistant 35S-MoPrP bands were observed.
The PK-resistant bands observed were 25-30 kDa, 19-21 kDa, and 15 kDa
(Fig. 4.1). These different bands were probably due to the variable glycosylation
of the MoPrPC. As with the hamster conversion, the presence of the bands
required the presence of the MoPrPsc preparation during incubation at 370 C.
The MoPrPC was initially converted in 0.75 M GdnHC1, but an increase in
GdnHCl during conversion yielded a higher percent of conversion. GdnHCl
concentrations from 1 to 6 M were used during the incubation to optimize the
conversion efficiency. Incubation in 2 M GdnHCl gave the most efficient
conversion although 1 and 3 M produced lesser amounts of identical bands (Fig.
4.2). This was very different from the hamster system where an incubation at 2
M GdnHCl produced very little protease resistant material (Fig. 4.3). These
experiments showed that other species PrPs could be used in this conversion
system, but that there were differences in how to achieve a maximum
conversion.
One somewhat disturbing aspect of the conversion using Chandler strain
MoPrPS c was that the products generated after PK treatment are reduced about
10-12 kDa. PK treatment of hamster and mouse brain derived PrPSc reduced its
mass 6-7 kDa as was also seen with the cell-free conversion of 35S-HaPrPC. The
formation of these bands was dependent upon the presence of MoPrPsc, but this
increased amount of PK cleavage indicated that 35S-MoPrpSc may not have been
fully formed. It is possible that a PK-resistant conformation of PrP was
generated that was different from MoPrPSc or intermediate between MoPrPC and
MoPrPSc . However, when a different strain of MoPrPsc called 87V was later
used, the PK-resistant bands were reduced by the expected 6-7 kDa (data not
shown). This could be another example of strain differences seen using this cell-
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free conversion system covered in chapter 5. Other conversions using 87V are in
progress. Again, the infectivity of PK-resistant MoPrP compared with brain
derived MoPrPsc could not be determined because of the vast amount of pre-
existing mouse infectivity.
Conversion experiments using combinations of HaPrP and MoPrP
With homogenous combinations of Ha and MoPrPs working, conversion
reactions were done using different species. 35S-MoPrPC incubated with
HaPrPSc and treated as before for the optimal hamster or mouse conversion
yielded no PK-resistant material (Fig. 4.1, compare lanes 3 and 4). To learn if
glycosylation was interfering with the interspecies conversion, tunicamycin was
used during the labeling to prevent Asn glycosylation. A 25 kDa unglycosylated
MoPrPC resulted that was used in the conversion with Mo and HaPrPSc.
Incubation with MoPrPS c resulted in three bands between 12 and 15 kDa (Fig.
4.1, lane 8). Incubation with HaPrPSc resulted in little detectable conversion (lane
7), which showed that more than glycosylation was responsible for this in vitro
species barrier.
The conversion reaction using 35S-HaPrpC expressed with and without the
GPI anchor was performed with MoPrPsc. This combination yielded very
different results than the previous one. Figure 4.3 is a fluorogram that shows the
results of the incubation of the two 35S-HaPrpC constructs with MoPrPsc.
MoPrPSc was able to generate resistant bands with either construct, but they
were different from those generated by HaPrPSc. As an example, in lane 3 the
most intense band after incubation with MoPrPSc was 18 kDa compared to lane 2
which shows a 25 kDa band from HaPrPSc. Differences were also seen with the
GPI- HaPrPC construct shown in lanes 7 and 8 that depended on whether Ha or
MoPrPSC was present during the incubation.
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The reactions were incubated in different concentrations of GdnHC1 to see
if these species specific differences would continue. The mouse and hamster
reactions were performed at 2 M GdnHCl (the optimum for mouse-mouse
conversion) as well as 0.75 M (Fig. 4.3). The species dependent size differences
were similar in either GdnHCl concentration, but the extent of conversion was
different. Changing the concentration of GdnHCl during incubation did not
eliminate the species specificity.
35S-HaPrPC was eluted in either 3 or 7.5 M GdnHCl before being used in
the conversion reactions. The products of 3 and 7.5 M pretreated HaPrPC with
HaPrPS c were directly compared. No difference in their abilities to be converted
under otherwise identical conditions was seen (data not shown), providing
evidence that any additional denaturing done by the increased GdnHCl was not
important. For reasons mentioned earlier, all 35S-MoPrPC was pretreated in 7.5
M GdnHC1. Extra denaturation done by increased denaturant concentration was
only important when 35S-MoPrPC was used. It appeared that once the PrPC was
denatured to a certain extent, the only factor determining its conversion was the
species of PrPSc it was incubated with.
Conversion experiments of mouse and hamster chimeras with PrPsc
Experiments were done to determine if a specific region of PrP was
responsible for the species specificity of the conversion to a protease-resistant
form. Specific PrP sequence differences affecting the conversion would point to
direct PrPC-PrPSc interactions. At RML, chimeric PrPs were produced that
included portions of mouse and hamster sequence for use in cell culture
conversion studies. To be used in the cell-free conversion system they just had to
be immunoprecipitated as was done with the other constructs. As mentioned
before, there are 16 sequence differences between mouse and hamster PrP with
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two of the differences being missing residues. Figure 4.4 is a map of the
constructs that were used in conversion reactions with Ha or MoPrPSc.
Conversion experiments with the chimeras were done very similarly to
those described earlier. The chimeras and mouse and hamster PrPC were all
treated in 7.5 M GdnHCl and mixed with MoPrPSC or HaPrPSc that had been
treated in 3 M GdnHC1. One difference was that the incubation was in 1.25 M
GdnHCl which allowed conversion by Mo or HaPrPSc but was not optimal for
either one. The results from similar experiments in 0.75 and 2 M only differed
from 1.25 M GdnHCl in the extent of conversion in either case. All constructs
incubated with MoPrPsc produced PK-resistant bands (Fig. 4.5). Some minor
variation in the size of the major bands produced was seen, but this can be
explained by different levels of glycosylation from the different expressing cell
types. However, after incubation with HaPrPsc, only Mo/Ha 33, Mo/Ha 67, and
HaPrPC yielded obvious PK-resistant material. These products were up to 32
kDa in mass and the pattern was like that usually seen when PrPSc was treated
with PK. The HaPrPC GPI- construct converted as expected. Its banding pattern
was always different from the other constructs because of less glycosylation and
the missing membrane anchor.
The readily apparent feature of those constructs that significantly
converted in the presence of HaPrPSc was that the central PrP region was of the
hamster sequence. The difference between hamster and mouse sequences in that
region is only three amino acid residues. Differences in other regions did not
control if conversion occurred.
What is the cause of this in vitro species barrier?
The species barrier is a virus-like characteristic of the TSEs and
consequently, many have argued that this is evidence a mutable nucleic acid
genome is part of the infectious agent. However, no virus or scrapie-specific
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nucleic acid has been found to date. The argument can be made from this study
that it is caused through protein-protein interactions. The species barriers known
in vivo have been duplicated in this cell-free system. As before, some doubt
remains in interpretation of these results because the purity of the PrPSC used is
not 100% and the presence of some important contaminant can not be ruled out.
Regardless of the possible presence of some important contaminant, the species
specificity in conversion of PrPC to the protease-resistant form depends at least in
part upon the PrP sequences in the reaction.
A central observation here is that MoPrPSc and HaPrPSc converted
identical HaPrPC into products that had different PK sensitivities. One
interpretation of this result is that the different PrPScs induced different
conformations in the PrPC. The different conformations caused it to be cleaved
differently by PK which would explain the different sized bands seen.
Aggregates of different PrPsc could lead to the formation of different
conformations in converted PrPC through a seeded polymerization mechanism,
for instance.
This in vitro species barrier seems to correlate with the in vivo data on
transmission of 263K and Chandler scrapie between mice and hamsters.
Hamster 263K scrapie is not transmissible to mice. Correspondingly, there was
no conversion of MoPrPC to the resistant form using HaPrPSc. MoPrPC is
converted to MoPrPS c when mice get scrapie. Chandler scrapie is transmissible
to hamsters but an extended incubation time is required. The fact that MoPrPSC
converts HaPrPC to a form with a different protease sensitivity than HaPrPsc
may account for this extension. The conformation of HaPrPC induced by
MoPrPsc may be less pathogenic than generated by HaPrPSc, accounting for the
delayed onset seen in vivo. If PrPC converting to a protease-resistant form is
113
equivalent to the pathology of the disease, this data correlates with the biological
data available.
A difference of three amino acids was sufficient to stop the conversion to a
resistant form. Mo/Ha 40 and Mo/Ha 67 only differ at residues 139, 155, and
170. The changes in the sequence going from the hamster to the mouse sequence
(Met 139-Ile, Asn 155-Tyr, Asn 170-Ser) are conservative and occur in a
hydrophilic region of PrP. These residues were essential if a protease resistant
form was going to be induced with HaPrPSc. Since MoPrPSC converted all Mo
and HaPrPC to resistant forms, it is not surprising that it converted all chimeras
as well. Because these residues occur in a hydrophilic region, it is reasonable to
assume they be at the surface of PrPC and could be available to react with PrPSc
during the conversion. Experiments are in progress using MoPrPC with only
residues 139, 155, or 170 changed to the hamster version.
If the 135-175 region is responsible for the species barriers seen in the TSEs
then it is of interest to see how these regions compare between other species.
Between bovine and ovine PrP there are differences at 143, 155, and 168, three in
all as is the case between hamster and mouse. Human and bovine are different at
138, 166, and 168, while human and ovine have differences at 138, 143, 155, 166,
and 168. The apparent lack of transmission of scrapie from sheep to humans
could be due to the extra differences in the 135-175 region, but cell culture studies
have demonstrated that one differing residue (138) is sufficient to prevent
conversion to PrPSc using mouse and hamster sequences. Perhaps cows might be
more susceptible to sheep scrapie because there is no difference at 138. The
human sequence differs from ovine and bovine at residue 138 which hopefully
lowers human susceptibility to BSE. Clearly more than just the number of
sequence differences is important. The direction of transmission is also
important as hamster 263K scrapie will not cause disease in mice, but Chandler
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mouse scrapie will cause disease in hamsters. Sheep scrapie might not be
infectious to humans, but passed through cows as BSE it might be. Cell-free
conversion experiments are currently in progress using human, bovine, and
ovine PrPCs and PrPSC. These experiments will determine if the sequences are
compatible using in vitro conditions. However, the exact correlation between in
vitro compatibility and infectivity is unclear.
For PrPSC to be the infectious agent in scrapie it has to be capable of
explaining the species barriers that are encountered. According to this study,7
except for the possibility of a biological contaminant that copurifies with PrPSc,
direct protein-protein interactions can explain species barriers. Different species
PrPs have various sequence differences which could be expected to vary their
structures enough to change compatibilities on a molecular level. The more
compatible that the sequences are, the more likely that a TSE will be
transmissible between them.
Figure 4.1 Conversion of glycosylated (Mo) or tunicamycin-treated (+tun) 35S-
MoPrPC to PK-resistant forms in the presence of MoPrPSc or HaPrPSc. Without
PK treatment, the glycosylated 35S-MoPrPC precursor consisted of 25-40 kDa
bands (lane 1) and the unglycosylated form migrated at approximately 25 kDa
(lane 5). All PrPC used here was eluted from protein A sepharose in 7.5 M
GdnHCI and incubated in 2 M GdnHC1. PK-treated lanes contained twice the
reaction equivalents loaded into the non PK-treated lanes. Molecular weight
markers are indicated in kDa at the left.
Figure 4.2 The effect of GdnHCI concentration on conversion of MoPrPC to a
resistant form using MoPrPS c. Lane 1 was non PK-treated 35S-MoPrpC
precursor. Lanes 2-6 were PK-treated 35S-MoPrpC after incubation with MoPrPSC
at the indicated GdnHC1. Notice how there was no conversion in 4.5 or 6 M
GdnHCl and that the only difference in the 1, 2, and 3 M lanes was the intensity
of the signal. The concentration of GdnHC1 was made 1 M for all samples before
adding PK. Lane 1 contained 7 times fewer reaction equivalent than the other
lanes. Molecular weight markers are indicated in kilodaltons at the left.
Figure 4.3 Conversion of HaPrPC to resistant forms using HaPrPSc and MoPrPSc.
Without PK treatment, the 35S-HaPrPC precursor consisted of 25-40 kDa bands
115
and a 60 kDa dimer (lane 1) and the 35S-HaPrPC GPI- construct consisted
predominantly of an unglycosylated (24 kDa) form (lane 6). All HaPrPC used
here was eluted from protein A sepharose in 3 M GdnHCl and incubated in 0.75
or 2 M GdnHC1. All PK-treated lanes contained 7 times the reaction equivalents
loaded into the non PK-treated lanes. Molecular weight markers are indicated in
kDa at the left.
Figure 4.4 Map of the mouse, hamster, and chimeric PrPC forms used in Figure
4.5. Shaded areas indicate regions that were derived from hamster DNA and
open areas were from mouse. Tick marks indicate where amino acid residues
differ between mouse and hamster PrP and the ticks over the bars designate the
presence of a hamster residue in that position. 16 differences are indicated
between hamster and mouse sequences. NaeI and BstEII refer to the sites where
the different DNAs were joined. The five numbered residues were present in all
constructs that converted to resistant forms with HaPrPSc. A plus to the right of
a bar signifies that the construct converted to a resistant form after incubation
with the indicated PrPSc . Notice that all constructs that converted with HaPrPSc
had hamster residues (methionines) at residues 109 and 112 (partially defining
the 3F4 epitope) but these residues were not sufficient for conversion with
HaPrPSc as indicated by the lack of conversion of Mo-3F4.
Figure 4.5 The conversion of chimeric mouse/hamster PrPCs to PK-resistant
forms in the presence of HaPrPSc or MoPrPSc. The constructs were pretreated
with 7.5 M GdnHCl and the incubation with PrPSC was at 1.25 M GdnHC1. Lanes
1-7 illustrate the untreated 35S-PrPC constructs. Lanes 8-21 were the constructs
after incubation with PrPSc and PK treatment. Molecular weight markers are
indicated in kDa at the left.
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Experimental
Preparation of MoPrPSC
The MoPrPsc was purified using the procedure for HaPrPSc described in
chapter 2. The source of MoPrPsc was mouse brains infected with Chandler
strain scrapie. The preparations were used directly from a suspension in 1%
sulfobetaine 3-14 and phosphate buffered saline.
Formation of mouse/hamster chimeras
Mo-3F4, which is MoPrP containing the hamster reactive 3F4 antibody
epitope (Met 109 and Met 112) and a unique Nae I site has been described.8 Two
mouse/hamster PrP chimeras, Mo/Ha 33 and Mo/Ha 40, were derived by
utilizing the unique Nae I site within HaPrP and Mo-3F4 as described.9' 10
Additional recombinants Mo/Ha 66 and Mo/Ha 67 were derived by PCR
mutagenesis using standard techniques.
Recombinant PrP molecules were expressed in normal mouse
neuroblastoma (MNB) cells using the pSFF retroviral expression system. Cells
expressing the other recombinant PrP molecules were derived by limited dilution
cloning of bulk cultures of MNB cells expressing recombinant PrP molecules
according to published procedures. 9' 10
Labeling of mouse and mouse/hamster chimeric PrPc
Chimeric mouse/hamster PrPc was labeled with 35S methionine and
cysteine and immunoprecipitated from lysed cells using 3F4, a mouse
monoclonal antibody, which reacted with hamster PrP and all of the chimeric
PrPs containing the 3F4 epitope. In the case of MoPrP, which lacked the 3F4
epitope, R30,11 a rabbit polyclonal antiserum raised against PrP 90-104 was used.
The PrP-antibody complexes are eluted from protein A sepharose in either 3 or
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7.5 M GdnHC1. Except for the use of different antibodies and different GdnHC1
concentrations during elution, the labeling is done as was stated in chapter 2.
Conversion of mouse and mouse/hamster chimeric PrPCs to protease-resistant forms
Conversion of these PrPCs to resistant forms was done with small changes
on the basic reaction mentioned in chapter 2. MoPrPC was eluted in 7.5 M
GdnHCl and mixed with MoPrPS c and then diluted to 2M GdnHC1, the optimal
concentration. After incubation and before PK treatment, the mixture was
further diluted to 0.25 M GdnHC1 using additional TN solution. The remainder
of the procedure was done exactly as stated for conversion of HaPrPC.
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Chapter 5
Cell-free conversion of PrP into strain-specific protease resistant forms
Another virus-like characteristic of the TSEs is the existence of strains
within the same species. Strains are identified through specific pathological
features such as specific patterns of degeneration in the brain, different areas of
the brain being affected, and the appearance of different clinical symptoms.
Different strains are also noted for having different incubation times. The
differences seen are analogous to variations in a disease caused by different
strains of a virus. Many strains are stable when passaged between the same
species of host and the pathology will not vary. No scrapie virus ever being
identified, the question remains of what causes TSE strains. If PrPsc is the sole
component of the infectious agent, then strains must be caused by propagated
structural differences. 1' 2
The propagation of strains can be tested in this cell-free conversion
system. The problem is that while all different strains produce infectious PrPSC,
in general, the pathology of newly formed infectivity would have to be
monitored to know if a strain had been propagated. As was mentioned before,
this system has too much pre-existing infectivity to determine if the strain
characteristics had been passed. Strains were needed that produced PrPSC with a
readily observable biochemical difference.
Two scrapie strains in Syrian golden hamsters that were suitable for use in
the cell-free conversion system were named hyper (HY) and drowsy (DY).1, 3
These strains originated from the inoculation of transmissible mink
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encephalopathy infected brain homogenate into hamsters. As with other strains
these have varying incubation times and clinical symptoms. However, the PrPSc
from these strains has different sensitivities to PK cleavage and the N-terminal
cleavage sites are different. A 1-2 kDa difference was seen after treatment with
PK (Fig. 5.1a). Differences in the biochemical properties of other strains of PrPS&
have been reported, but not as dramatic and reproducible as these. This
difference could be interpreted to be due to different conformations. This
presented an ideal situation for the cell-free system because if strain-specific N-
terminal cleavage sites could be passed it would be readily observed without
having to monitor infectivity.
Conversion experiments done using HY and DY PrPSC
HY and DY PrPSc for use in the cell-free conversion system was purified
from infected hamster brains according to the procedure used for the Ha and
MoPrPSc. The 35S-HaPrPC used was the GPI- form and it was
immunoprecipitated to purify it as was done before. The reaction was performed
as in earlier attempts by mixing the 35S-HaPrpC with 3 M GdnHCI treated DY or
HY PrPSc and then diluting to 0.75 M and incubating for two days. PK treatment
and the rest of the procedure was done as before. The results of these
conversions are shown in figure 5.1b. Similar differences in the truncation by PK
of the converted material were present that depended upon the presence of a
specific strain. 35S-HaPrpC incubated with DY PrPSc was PK-resistant, but
allowed an extra 1-2 kDa to be cleaved just as seen in DY PrPsc from infected
brains. The major 24 kDa 35S-PrpC precursor was reduced in molecular weight
to 16 or 17 kDa depending on which strain of PrPSc was present. As was
demonstrated, incubation without the presence of any PrPSC prevented the
formation of protease resistant material.
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The efficiency of conversion of 35S-PrPC to a PK-resistant form was greater
when incubated with HY PrPSC than DY PrPSC. When equal amounts of labeled
PrPC were incubated with equal amounts of HY or DY PrPSc much more
protease resistant material was seen (Fig. 5.1b, compare lanes 1 and 2). A 16-fold
increase in DY concentration relative to HY PrPSc resulted in approximately
equal conversions based on the signal after PK treatment (lanes 3 and 4).
Another control was done to eliminate the possibility that more rigorous
treatments with PK would further cleave the product of incubation with HY
PrPSc to similar products as with DY PrPSC. Treatments of 0, 50, and 500 gg/mL
PK were done on the conversion reaction mixture after incubation. As shown in
Fig 5.1c, no formation of 16 kDa resistant bands occurred after incubation with
HY PrPSC and extra PK treatment. The only difference was elimination of
additional newly-converted labeled PrP from mixtures incubated with either
PrPSc. The extra elimination was expected because long protease treatments (>24
hours) will eventually eliminate all PrPSc.
The conversion reaction was done with varying GdnHC1 concentration
during incubation to see if that affected strain differences. As is shown in figure
5.2, the extent of conversion was affected in different GdnHC1. No conversion
occurred in 3 M, but it did in 1 or 2 M. Between 1 and 2 M only the extent of
conversion was affected and the strain-specific differences remained. It does not
appear that the differences were related to the GdnHCl concentration used in the
reaction. The fact that strain-specific differences were maintained under a
variety of conditions is evidence that they are due to stable differences between
HY and DY PrPsc.
In vivo data correlates with the conversion observed using HY and DY
PrPsc. There is a 100 fold greater concentration of infectivity in the HY infected
brain than in the DY at the time of onset of disease, even though similar amounts
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of PrPsc are present. In the cell-free system, approximately 16 fold more DY was
needed to equal the conversion with HY. If accumulation of PrPsc is the major
factor in disease progression, less infectivity per amount of PrPsc preparation
correlates to lower levels of conversion in the cell-free system.
Conversion is enhanced by the presence of cationic detergents
Detergents added to the cell-free conversion reaction increased the percent
of PK-resistant product formed. Cetyl pyridinium chloride (CPC), cetyl
trimethyl ammonium bromide (CTAB), and triton X-100 below their critical
micelle concentrations were included. 1.5 mM CPC or CTAB improved the
extent of conversion (Fig. 5.3) to at least 30%. Compared to a reaction with no
detergent, triton X-100 inhibited conversion. Decreasing the amount of CPC or
CTAB decreased the enhancement and when less triton X-100 was present the
inhibition was decreased. Controls were done that showed CPC alone cannot
cause PrP to become protease-resistant and also that CPC does not inhibit PK
(data not shown). CPC and CTAB are cationic detergents and CPC is actually an
ingredient of mouthwash. Why they enhanced the reaction is unknown. It can be
speculated that they help solubilize the reactants which boosted the conversion
or mimic the membrane conditions that PrP experiences as it is bound to the cell
surface. Triton X-100 is an anionic detergent and why it inhibited is again
unknown.
CPC was added to the conversion using HY and DY PrPSc to see if the
conversion would be enhanced and also if the strain differences would remain.
1.5 mM CPC improved the extent of conversion as much as 3.5 fold with HY and
14 fold with DY (Fig. 5.4). CPC also slightly altered the pattern of PK-resistant
bands seen, but strain-specific differences were maintained.
PrPSC treated with PK causes conversion of PrP to the protease-resistant form
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HY and DY PrPsc that had been pretreated with PK and then used in the
conversion reaction as before yielded the same resistant bands as seen previously
with strain differences being maintained (Fig 5.5). The treatment with PK prior
to use in the conversion reaction resulted in a more pure PrPSC preparation; other
minor protein impurities are largely eliminated. In the case of HY and DY PrPSC,
the cleavage is at different sites but does not affect the strain differences. PK-
treated PrPSC causing conversion is additional evidence that PrP interactions are
sufficient for conversion to occur. A protein cofactor would have to copurify
with PrP and also be protease-resistant. Of course potential non-protein
cofactors would be unaffected.
When PK-treated PrPSc was used in the conversion system, the presence
of PK must be taken into account. Trace amounts were likely to be present even
after washing and pelleting steps. The conversion using PK-treated PrPSc
worked poorly without CPC present (data not shown) and this could be because
of residual PK digesting 35S-PrPC in the conversion mixture. It is possible that
CPC sped up the reaction so digestion of the 35S-PrPC by residual PK was
minimized.
Glycosylation does not account for the strain-specific differences in converted PrPc
The major band of the 35S-PrPC GPI- construct was a 24 kDa
unglycosylated species. Some 28 kDa monoglycosylated PrP was present with
the unglycosylated material. To make certain that glycosylation of the PrPC was
not a factor in strain differences, PrPC from tunicamycin treated cells was
immunoprecipitated as before. This unglycosylated 35S-PrPC GPI- was used in
the conversion reaction as stated above. The results of the conversion done with
exclusively unglycosylated PrPC indicated that the strain difference was
maintained (Fig. 5.6). This experiment showed that the different forms were
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derived from identical precursor material which consisted of a polypeptide of
approximately 209 amino acids.
Evidence that protein alone can account for TSE strains
TSE strains are a virus-like property and have been difficult to explain
using a protein-only hypothesis. Strains occur in the same species so there is no
difference in primary PrP sequence as is the case in the species barriers. In this
study4 the identical 209 amino acid sequence of the PrPC GPI- construct was
converted into different protease resistant forms through incubation with HY or
DY PrPSC preparations. Because the precursor sequences were identical, it makes
it likely that the differences were due to different tertiary or quartenary structure.
A precedented mechanism for PrPsc formation based on nucleated
polymerization has been proposed.5, 6 Using this model the strains can be
reconciled with a protein only hypothesis of TSE infection (Fig. 5.7). In this
scenario, scrapie strains are alternative conformations or different packing
arrangements of similar conformations in PrPSC polymers, analogous to different
crystal forms seen in the same protein. Although many proteins self-assemble
into polymers by nucleation-dependent polymerization, this model of TSEs
would be the first example of an infectious pathogen using only this mechanism
for replication and strain variation. This data shows that the preexisting PrPSc
can determine the structure of the newly formed PrPSc is consistent with this
model. These results also show that the chemical conditions of the reaction can
strongly affect the efficiency of the conversion. It is conceivable that diversity of
the chemical or physiological conditions within the brain could determine the
strain-specific tissue distribution of HY and DY PrPSc and the rate of PrPsc
formation. These differences in PrPSC formation can determine the strain specific
clinical and pathological features among scrapie diseases.
135
Figure 5.1 Strain-specific cell-free conversion of PrPC to PK resistant PrP. a,
Immunoblot of purified brain derived PrPS c from HY (H) and DY (D) scrapie
infected hamsters digested with PK. Note the 1 kDa faster migration of DY PrPsc
compared to HY PrPsc. b, 2 jgg of HY and DY PrPSC (lanes 1 and 2), or 0.25 Rig of
HY PrPSC (lane 3) and 4 jg DY PrPSC (lane 4), were combined with approximately
60,000 cpm of 35S-PrPC in the conversion reactions. Lane 5 contains 10,000 cpm
of 35S-PrpC. c, Cell-free conversion products digested with increasing amounts
of PK. Conversion reaction 35S-PrP products were analyzed by 15% SDS-PAGE
and fluorography. The major recombinant 35S-PrpC had a molecular weight of
24 kDa (indicated by the arrowhead) which was smaller than the hamster brain
derived PrPC (33-35 kDa) because it lacked N-linked glycans and a GPI anchor.
These differences between the sources of PrPC can also explain why the banding
pattern of the PK resistant 35S-PrP in SDS-PAGE were not identical to the three
PK resistant bands derived from hamster brain PrPC. In some experiments,
residual levels of the 24 kDa 35S-PrpC were present after PK digestion. Similar
amounts of HY and DY PrPSC were present after PK digestion as determined by
PrP immunoblots and silver stained SDS-PAGE (data not shown). Molecular
weight markers are indicated at the tick marks.
Figure 5.2 The effects of GdnHC1 on the strain-specific PrP conversion reactions.
The final GdnHCl concentration in the reaction was adjusted to either 1, 2, or 3
M. The reactions were diluted to 0.4 M GdnHCL just prior to digestion with PK.
35S-PrpC in the absence (-) of PrPSC was not treated with PK. The arrowhead
marks the molecular weight of the 24 kDa 35S-PrpC precursor and the molecular
weight of the marker proteins is indicated at the left. The absence of PK resistant
products after incubation in 3 M GdnHCl was likely due to irreversible
denaturation of PrPSc rather than 35S-PrpC; pretreatment of 35S-PrPC with 7.5 M
GdnHC1 did not inhibit its conversion in earlier studies.
Figure 5.3 The effects of detergents on the conversion of 35S-PrpC to the
protease-resistant form. The first lane on the left shows the product of a
conversion reaction as described in the legend of Fig. 5.1 in the absence of
detergent. The next lanes were conversions done identically except for the
presence of the indicated amount of CPC or Triton X-100 in the reaction mixture.
All reactions contained 80,000 cpm of 35S-PrpC initially. Molecular weight
markers are indicated at the left in kilodaltons.
Figure 5.4 The effects of CPC on the strain specific PrP conversion reactions. The
conversion reaction was performed in the presence (+) or absence (-) of 1.5 mM
CPC. Molecular weight markers, in kilodaltons, are indicated at the right. In the
presence of CPC, the major PK resistant 35S-PrP conversion products had
molecular weights of 18 to 22 kDa after incubation with HY PrPSC. In the DY
PrPsc reaction, the addition of CPC did not change the migration of the major 16
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kDa conversion product although different minor conversion products were
formed.
Figure 5.5 Effect of PK pretreatment of PrPsc on the strain-specific cell-free
conversion reaction. HY and DY PrPS c were digested (+) with PK (pre) to
generate preparations highly enriched for PrPS c (>95% by SDS-PAGE).
Predigested and undigested (-) PrPsc were used in the cell-free conversion assay
followed by the PK digestion step (post), as described in Fig. 5.4. The arrowhead
marks the 24 kDa 35S-PrPC GPI- precursor.
Figure 5.6 The conversion of unglycosylated 35S-PrpC to PK resistant forms.
Cells treated with or without 15 gg/mL tunicamycin were immunoprecipitated
and the untreated labels are shown in lanes 1 and 2. The arrow points to the
monoglycosylated 28 kDa form and the arrowhead points to the unglycosylated
24 kDa form. Conversion reactions were done with glycosylated and
unglycosylated 35S-PrpC with HY (H) and DY (D) PrPSC. Note that the banding
patterns are identical. Molecular weight markers are indicated at the right in
kilodaltons.
Figure 5.7 Nucleation-dependent protein polymerization model for strain
differences in scrapie and other TSEs. Monomeric PrPC is soluble and kinetically
stable. In the presence of a PrPsc nucleus or seed, which is an ordered polymer,
growth by addition of a PrP monomer (indicated by shaded rectangles) is
favored. The monomeric PrPC or, perhaps, an unfolded intermediate (PrPu)
acquired a new conformation that is stabilized by intermolecular interactions
within the PrPSc polymer. In this model, strain differences would be due to
PrPsc polymers that have distinct packing arrangements and/or conformations.
The same monomeric PrP conformer could be packed into differently arranged
PrPSC polymers (as illustrated in the figure) or distinct PrP conformers could be
incorporated into different PrP s c polymers. PK digestion of different PrPSC
polymers could generate distinct cleavage products even if they are derived from
the same PrPC precursor.
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